Attached files
file | filename |
---|---|
EX-11 - EX-11 - PROFESSIONAL VETERINARY PRODUCTS LTD /NE/ | c54309exv11.htm |
EX-12 - EX-12 - PROFESSIONAL VETERINARY PRODUCTS LTD /NE/ | c54309exv12.htm |
EX-32 - EX-32 - PROFESSIONAL VETERINARY PRODUCTS LTD /NE/ | c54309exv32.htm |
EX-31.1.A - EX-31.1.A - PROFESSIONAL VETERINARY PRODUCTS LTD /NE/ | c54309exv31w1wa.htm |
EX-31.1.B - EX-31.1.B - PROFESSIONAL VETERINARY PRODUCTS LTD /NE/ | c54309exv31w1wb.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
þ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For the fiscal year ended July 31, 2009, or
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For the transition period from to .
Commission file number: 000-26326
PROFESSIONAL VETERINARY PRODUCTS, LTD.
(Exact name of Registrant as specified in its charter)
Nebraska | 37-1119387 | |
(State or other jurisdiction of | (IRS Employer | |
incorporation or organization) | Identification No.) |
10077 South 134th Street
Omaha, Nebraska 68138
(402) 331-4440
(Address and telephone number of Registrants principal executive offices)
Securities Registered Pursuant to Section 12(b) of the Act: None
Securities Registered Pursuant to Section 12(g) of the Act:
Common Stock, par value
$1.00 per share
(Title of Class)
Omaha, Nebraska 68138
(402) 331-4440
(Address and telephone number of Registrants principal executive offices)
Securities Registered Pursuant to Section 12(b) of the Act: None
Securities Registered Pursuant to Section 12(g) of the Act:
Common Stock, par value
$1.00 per share
(Title of Class)
Indicate by check mark if the Registrant is a well-known seasoned issuer; as defined in Rule 405 of the
Securities Act. Yes o No þ
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section
15 (d) of the Act. Yes o No þ
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the Registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). Yes o No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405
of this chapter) is not contained herein, and will not be contained, to the best of Registrants knowledge,
in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer o | Non-accelerated filer þ (Do not check if a smaller reporting company) |
Smaller reporting company o |
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the
Act).
Yes o No þ
As of January 31, 2009, the aggregate market value of the voting and non-voting Common Stock held
by non-affiliates of the Registrant was $5,899,000. Shares of Common Stock held by each executive
officer and director of the Registrant have been excluded in that such persons may be deemed to be
affiliates of the Registrant. This determination of affiliate status is not necessarily a
conclusive determination for other purposes. As of September 30, 2009, 1936 shares of the
Registrants Common Stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the definitive Proxy Statement for the Registrants 2010 Annual Meeting of
Stockholders to be filed within 120 days of the fiscal year ended July 31, 2009 are incorporated by
reference into Part III of this Annual Report on Form 10-K.
TABLE OF CONTENTS
Page | ||||||
PART I |
||||||
ITEM 1.
|
BUSINESS | 1 | ||||
ITEM 1A.
|
RISK FACTORS | 6 | ||||
ITEM 1B.
|
UNRESOLVED STAFF COMMENTS | 13 | ||||
ITEM 2.
|
PROPERTIES | 13 | ||||
ITEM 3.
|
LEGAL PROCEEDINGS | 14 | ||||
ITEM 4.
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS | 14 | ||||
PART II |
||||||
ITEM 5.
|
MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES | 15 | ||||
ITEM 6.
|
SELECTED FINANCIAL DATA | 16 | ||||
ITEM 7.
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 17 | ||||
ITEM 7A.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 28 | ||||
ITEM 8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 29 | ||||
ITEM 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE | 29 | ||||
ITEM 9A (T).
|
CONTROLS AND PROCEDURES | 29 | ||||
ITEM 9B.
|
OTHER INFORMATION | 31 | ||||
PART III |
||||||
ITEM 10.
|
DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE | 31 | ||||
ITEM 11.
|
EXECUTIVE COMPENSATION | 31 | ||||
ITEM 12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS | 31 | ||||
ITEM 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE | 31 | ||||
ITEM 14.
|
PRINCIPAL ACCOUNTING FEES AND SERVICES | 31 | ||||
PART IV |
||||||
ITEM 15.
|
EXHIBITS, FINANCIAL STATEMENTS SCHEDULES | 32 | ||||
SIGNATURES |
-i-
PART I
THIS REPORT CONTAINS FORWARD-LOOKING STATEMENTS BASED ON THE COMPANYS CURRENT EXPECTATIONS,
ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND ITS INDUSTRY. THESE FORWARD-LOOKING
STATEMENTS INVOLVE RISKS AND UNCERTAINTIES. THE COMPANYS ACTUAL RESULTS COULD DIFFER MATERIALLY
FROM THOSE ANTICIPATED IN SUCH FORWARD-LOOKING STATEMENTS AS A RESULT OF CERTAIN FACTORS, AS MORE
FULLY DESCRIBED ELSEWHERE IN THIS REPORT. THE COMPANY UNDERTAKES NO OBLIGATION TO UPDATE PUBLICLY
ANY FORWARD-LOOKING STATEMENTS FOR ANY REASON, EVEN IF NEW INFORMATION BECOMES AVAILABLE OR OTHER
EVENTS OCCUR IN THE FUTURE.
ITEM 1. | BUSINESS |
Overview
The Company is a leading wholesale distributor of animal health products to veterinarians and
their related businesses. The Company distributes to its customers approximately 20,000 different
products including biologicals, pharmaceuticals, parasiticides, instruments and equipment and also
offers industry-exclusive programs on inventory and staff management. Approximately 14,000 products
are inventoried for immediate shipment and the remaining items are either drop-shipped from the
manufacturer to the customer or are special order items. The Company primarily sells branded
products as marketed by the major animal health manufacturers and suppliers. The Company does not
currently private label any products.
The Company operates through three operating segments: Wholesale Distribution (PVPL),
Logistics Services (Exact Logistics), and Direct Customer Services (ProConn). The Wholesale
Distribution segment is a wholesaler of pharmaceuticals and other veterinary related items and
accounted for approximately 81% of net sales and other revenue during fiscal year 2009. This
segment distributes products to Company shareholders as well as other licensed veterinarians and
businesses comprised of veterinarians. See Managements Discussion and Analysis of Financial
Condition and Results of Operations Operating Segments below and Note 14 of the Companys 2009
Consolidated Financial Statements for quantitative segment information.
The Companys business strategy is to be the leading supplier of animal health products to
veterinarians and veterinary clinics by offering a complete assortment of items at competitive
prices which are supported by superior levels of customer service. The Company believes this
strategy provides it with a competitive advantage by combining the broad product selection with low
prices and support from efficient operations. By purchasing products from the Company,
veterinarians and veterinary clinics may reduce their product acquisition costs.
The Company has heavily invested in electronic information systems to maximize efficiencies.
All phases of the transactional process are electronically driven. The Company believes this
advanced electronic technology will assist in earlier adoption of electronic commerce through the
internet by both its customers and suppliers.
Background
The Company was founded in 1982 by veterinarians whose primary interests were food animal
related and was chartered on August 2, 1982 as a Missouri corporation. Since January 1, 1983, the
Company has operated from various facilities in Omaha, Nebraska. The Company surrendered its
Missouri charter and became a Nebraska corporation on September 22, 1999.
Initially, the Company distributed its products predominately to existing shareholders who
were veterinarians or business entities established to deliver veterinary services and/or products
in which medical decisions were made by licensed veterinarians. Each shareholder was and is limited
to ownership of one share of common stock. Sales to non-shareholder customers have increased in
recent years and have represented a significant source of revenue for the Company. In fiscal year
2009, net sales and other revenues to non-shareholders totaled $102 million or 34% of total net
sales and other revenue. The Companys fiscal year begins on August 1 and concludes on July 31 of
the following year.
Value-Added Services
The Company offers its customers and suppliers a comprehensive menu of value-added services.
These services allow individual customers to choose various selections based on their individual
needs such as on-line
1
ordering, inventory management, employee management, pharmacy and special order fulfillment.
The Company manages a database of all transactions so that its customers may maximize their
participation in promotions frequently offered by suppliers. Customers are periodically apprised,
either by phone or mailings, of their level of participation in these promotions. This promotional
tracking service gives customers the option to maximize their participation in promotions, which
may increase their profitability, increase Company sales and allow the customers to more
effectively compete in certain markets.
The Company has developed two multi-day seminars for its customers, which include an inventory
management and purchasing techniques seminar and an employee management and leadership seminar.
These seminars are held at various locations, often at one of the Companys properties. Customers
are trained to better use the Companys resources and also increase efficiency when managing their
product and inventory activities and to effectively manage employees and learn effective leadership
principles and skills for their clinics.
The Company has Electronic Data Interchange (EDI) capability which provides the supplier with
product sales and movement. The supplier is able to monitor sales activities, advertising
effectiveness and market trends in an efficient manner. The Company also assists the manufacturer
in the design of effective promotions. The historical transactional database and the promotional
tracking service are unique tools that assist the manufacturer in tailoring effective promotions.
The Company has enhanced the customer relationship by utilizing e-commerce. E-commerce enables
the customer to place orders on-line and view purchasing history 24 hours a day, seven days a week
through the Companys website.
In 2007, the Company launched Vets First Choice, a new online store and home delivery service.
Vets First Choice enables veterinarians to meet the demands of third party clients without
increasing their inventory costs.
Vets First Choice recently introduced the myPetLink feature, which offers pet owners access to
their pets medical records. Information is derived from vet clinics practice management systems
and is delivered in a secure online format that is user friendly. The myPetLink feature also
provides veterinarians the ability to set up automatic messaging to their clients, which may
include pet health bulletins, monthly newsletters and compliance reminders. Through this feature,
we believe that communication between veterinarians and their clients will improve.
The Company also recently announced that PVPL and ProConn will be marketed together under the
PVP brand. We believe that aligning our teams under one brand supports our long-term goals of
being a one-stop solution for veterinary practices and a leading advocate for the animal health
community as well as providing improved distributor experience. Although we intend to market one
brand name, our segment reporting will remain unchanged, and we will continue to report our results
of operations through our three operating segments: Wholesale Distribution (PVPL), Direct Customer
Services (ProConn) and Logistics Services (Exact Logistics).
New Facility and Services
The Company recently opened a small facility in Iowa Falls, Iowa. This facility will be
approximately 8,000 square feet and have two employees. Our customers may walk up to this
facility and purchase products immediately. During fiscal 2009, we also opened other facilities in
Quincy, Illinois, Mankato, Minnesota, and Spicer, Minnesota. See ITEM 2. PROPERTIES for
additional information. We also are investing in new pharmacy technology which we believe will
provide another service benefit to our customers.
Our Shareholders
As of July 31, 2009, the Company had 1,948 shareholders, all of whom were veterinarians or
veterinary clinics. These shareholders are principally located from the Rocky Mountains to the
Atlantic Seaboard with some presence in the southern United States. Our shareholders also are our
primary customers.
Rebates to Shareholders
Except for fiscal year 2008, the Company has historically issued rebates to its shareholders.
According to current practices of management, such rebates, if paid, are made on a pro rata basis
to shareholders based on the aggregate amount of products purchased by each shareholder during the
period. Rebates are included in the Companys financial statements and are netted against sales and
accounts receivable on the Companys financial statements. Depending on several factors, there is
no assurance that any rebate will be issued for a given fiscal year.
2
Corporate officers determine the amount, if any, to be returned to each shareholder. Such
amounts shall not include any amounts which the officers conclude are required for the ongoing
conduct or expansion of the Companys business. If the Company elects to pay a rebate, the Company
will issue to each shareholder an amount based upon the shareholders eligible product purchases
from the Company. If a shareholder is entitled to a rebate, the shareholder shall be issued a
credit memo at least once per fiscal year. The determination by the officers, upon approval of the
Board of Directors, of whether or not a rebate is issued, the terms of the rebate and the
communication of such terms to the shareholder constitutes an obligation on the part of the Company
to issue the credit memo.
The Companys policies and procedures address concerns regarding late payments by shareholders
and the payment of a rebate. The determination of the amount rebated back to shareholders by credit
memo during any fiscal year includes a review of whether the respective shareholder made timely
payments to the Company and whether there are any past due invoices over 90 days as of the end of
the fiscal year. The Company determines the shareholders average days to pay which is the number
of days past the due date on which the Company receives the shareholder payment. If the average
days to pay exceed 30 days, the amount of the rebate credited back to the shareholder is reduced
according to the Companys then current reduction percentage policy. If a shareholder has any
unpaid amount which is more than 90 days past due as of the fiscal year end, no rebate will be
issued to the shareholder for that fiscal year.
Company Subsidiaries
The Company has two direct wholly-owned subsidiaries: Exact Logistics, LLC (Exact Logistics)
and ProConn, LLC (ProConn). Exact Logistics and ProConn were organized in the State of Nebraska
on December 6, 2000 and are limited liability companies wholly-owned by the Company. The purpose of
Exact Logistics is to provide logistics and distribution service operations for animal health
vendors in business-to-business type transactions. Exact Logistics distributes products primarily
to other animal health companies.
The purpose of ProConn is to act as a supplier of animal health products directly to the
producer and/or consumer. Producers and end users order veterinary products directly from ProConn.
ProConn then sells and delivers the products directly to producers and consumers. ProConn is
responsible for all shipping, billing and related services. As part of its business operations,
ProConn may enter into an agreement with veterinarians of record pursuant to which ProConn agrees
to pay the veterinarian of record a percentage of the sale received by ProConn from qualified
purchases. The veterinarian of record is responsible for providing various services to the
producers and consumers, including, without limitation, conducting on-site visits of producers
facilities, reviewing the producers or consumers data pertaining to purchases from ProConn, and
maintaining compliance with all pharmaceutical-related laws, regulations and any applicable food
safety guidelines.
Operating Segments
The Company has three reportable segments: Wholesale Distribution (PVP), Direct Customer
Services (ProConn), and Logistics Services (Exact Logistics). Additional information including the
sales and operating profits of each operating segment and the identifiable assets attributable to
each operating segment for each of the three years in the period ended July 31, 2009 is set forth
in the Managements Discussion and Analysis of Financial Condition and Results of Operations and
in Note 14 of the 2009 Consolidated Financial Statements.
Financial Information About Geographic Areas
All of the Companys customers and assets are located in the United States. The Company does
not export any products outside of the United States.
Customers and Suppliers
Management does not consider the Companys business to be dependent on a single customer or a
few customers, and the loss of any of our customers would not have a material adverse effect on our
results. No customer accounted for more than 5% of the Companys total net sales and other revenue
for fiscal 2009. The Company typically does not enter into long-term contracts with its customers.
To offset the loss of any customers, the Company continually seeks to diversify its customer base.
We believe that consolidation of small privately owned veterinary clinics is likely and will
result in an increasing number of larger veterinary practice business units. As a result, the
larger veterinary practices will have
3
increased purchasing leverage and will negotiate for lower product costs which will reduce
margins at the distribution level and impact Company revenue and net income.
There are two major types of transactions that affect the flow of products to the Companys
customers. The first transaction model is traditional buy/sell transactions that account for a
significant majority of the Companys business. In this type of transaction the customer places an
order with the Company, which is then picked, packed, shipped, invoiced to the customer, followed
by payment from the customer to the Company. There are a few product lines where the Company
provides all transactional activities described above, except that the manufacturer retains title
to the product. The manufacturer retains title in accordance with the distribution agreements for
these products. The Company inventories these products for the manufacturer but does not pay the
manufacturer until the product is sold to the customer and reported to the manufacturer. The
Company is responsible for maintaining insurance on the products but the value of the product is
not included in the inventory for accounting purposes.
A second transaction model used by the Company is termed the agency agreement. Under this
approach, the Company receives orders for products from its customers. The Company transmits the
order to the manufacturer who then picks, packs, ships, invoices and collects payment from the
customer. The Company receives a commission payment from the manufacturer for soliciting the order
as well as for providing other customer service activities. The Companys operating expenses
associated with this type of sale may be lower than the traditional buy/sell transaction. This
arrangement allows the manufacturer to establish and standardize the price of its products in the
market. The mode of selling products to veterinarians is dictated by the manufacturer.
Product returns from our customers and to our suppliers occur in the ordinary course of
business. The Company extends to its customers the same return of goods policies as extended to the
Company by the various suppliers. The Company does not believe its operations will be adversely
impacted due to the return of products.
Two vendors comprised 52.2% of all purchases for the year ended July 31, 2009. Two vendors
comprised 48.3% of all purchases for the year ended July 31, 2008. Management believes the loss of
any major vendor may have a material adverse effect on our results of operation, including the loss
of one or both of our two largest vendors. Currently, the Company believes that its relationships
with its two largest vendors are good.
The Animal Health Industry
Animal health product sales in the United States for 2008 were $6.8 billion which is unchanged
from the previous year. Modest price increases across many lines kept the sales flat for the year;
however, the actual product unit sales decreased for the same time period. The market for animal
health products in the United States is split between products sold for companion and production
animals. Companion animals include dogs, cats, other pets and horses, while production animals
include cattle and other food-producing animals. In 2008, companion animal products accounted for
approximately 54% of the total market, and production animal products comprised approximately 46%
of the animal health products market.
In the current economic environment, the animal health market has ceased its historic growth
phase. However, two factors work in favor of the industry pet owners love for their companion
animals and the economic reasons for the treatment of livestock or farm animals. We believe growth
in the companion animal health products market has slowed as result of a decrease in consumer
spending. Recently, there has been a slight reduction in pet ownership and many pet owners are
being forced to decrease their expenditures. Historically, the growth in the companion animal
health market was impacted by an increasing number of households with pets, an aging pet
population, increased expenditures on pets health and preventative care and advancements in new
animal health products. Product sales in the production animal health products market have been
heavily impacted by increasing volatility in commodity prices, changes in weather patterns
including drought in vast geographic areas of the United States, decreased export demand for animal
protein products, changes in consumer dietary preferences and changes in the general economy.
The impact of unprecedented price volatility in commodities such as corn and other grains, which
are primary livestock ration, have made it increasingly more difficult to predict the timing of
demand for production animal health products. Historically, sales in this market have been largely
driven by spending on animal health products to improve productivity, weight gains and disease
prevention, as well as a growing focus on food safety.
Veterinarians are one of the primary purchasers of animal health products, particularly in the
companion animal market. There are more than 58,000 veterinarians in private practice in the
United States. Over three-quarters of the veterinarians in private clinical practice predominantly
specialize in companion animal medicine.
Distributors play a vital role for both veterinary practices and livestock producers by
providing access to a broad selection of products through a single channel and helping them
efficiently manage their inventory levels.
4
Distributors also offer product vendors substantial value by providing cost-effective access
to a highly fragmented and geographically diverse customer base.
Competition
Distribution of animal health products is characterized by either ethical or OTC channels
of product movement. Ethical distribution is defined as those sales of goods to licensed
veterinarians for use in their professional practice. Many of these products are prescription and
must only be sold to a licensed professional. OTC (over-the-counter) distribution is the movement
of non-prescription goods to the animal owner and the end user. Many of these products will also be
purchased by licensed veterinarians for professional use or for resale to their clients.
There are numerous ethical distribution companies operating in the same geographical regions
as the Company and competition in this distribution industry is intense. Our competitors include
other animal health distribution companies and manufacturers of animal health products who sell
directly to veterinarians and veterinary clinics. Most of the animal health distribution
competitors generally offer a similar range of products at prices often comparable to the
Companys. The Company seeks to distinguish itself from its competitors by offering a higher level
of customer service and having its principal customers also be its shareholders. In addition to
competition from other distributors, the Company also faces existing and potentially increased
competition from manufacturers who distribute their products directly to veterinarians.
The role of the animal health distributor has changed dramatically during the last decade.
Currently, there is over capacity in the animal health distribution network, although there have
been few animal health distributor mergers or acquisitions. We believe the Company must continue to
add value to the distribution channel, and reduce the redundancies that exist, while removing
unnecessary costs associated with product movement.
Government Regulation
Both state and federal government agencies regulate the manufacturing and distribution of
certain animal health products such as pharmaceuticals, vaccines, insecticides and certain
controlled substances. Our suppliers of these products are typically regulated by one or more of
the following federal agencies, the U.S. Department of Agriculture (USDA), the Food and Drug
Administration (FDA) and the Drug Enforcement Administration (DEA), as well as several state
agencies; and therefore, the Company is subject, either directly or indirectly, to regulation by
the same agencies. Several states and the DEA require the Company to be registered or otherwise
keep a current permit or license to handle controlled substances. Manufacturers of vaccines are
required by the USDA to comply with various storage and shipping criteria and requirements for the
vaccines. To the extent the Company distributes such products, the Company must comply with the
same USDA, FDA and DEA requirements including, without limitation, the storage and shipping
requirements for vaccines.
Effective December 1, 2006, the FDA adopted a new rule establishing a pedigree requirement for
prescription drugs. A drug pedigree is a statement of origin that identifies each prior sale,
purchase, or trade of a drug, including the date of those transactions and the names and addresses
of all parties to them. Under the pedigree requirement, each person who is engaged in the wholesale
distribution of a prescription drug in interstate commerce, who is not the manufacturer or an
authorized distributor of record for that drug, must provide to the person who receives the drug a
pedigree for that drug. The Company currently is complying with the pedigree requirements.
Several State Boards of Pharmacy require the Company to be licensed in their respective states
for the sale of animal health products within their jurisdictions. Some states (as well as certain
cities and counties) require the Company to collect sales/use taxes on differing types of animal
health products.
Environmental Considerations
The Company does not manufacture, re-label or in any way alter the composition or packaging of
products. All products are distributed in compliance with the relevant rules and regulations as
approved by various state and federal regulatory agencies. The Companys business practices
minimally impact the environment.
5
Employees
As of July 31, 2009 the Company had 337 employees. We are not subject to any collective
bargaining agreements and have not experienced any work stoppages. We believe that we have a stable
and productive workforce and consider our relationships with our employees to be good.
Trademarks
The Company has federal registrations for the marks PVP LTD and design, PVP and design,
POWERING YOUR PRACTICE, PVP POWERING YOUR PRACTICE and design, PVPL, and PROCONN. The
Company has an application pending with the United States Patent and Trademark Office for the mark
IMPACT. Additionally, the Company uses the marks EXACT LOGISTICS and VETS FIRST CHOICE, but
does not have federal registrations or applications pending with the United States Patent and
Trademark Office for these marks. The Company believes that the marks are well recognized in the
animal health products industry and by veterinarians and therefore are valuable assets. Once
registered, the trademarks will be valid as long as they are in use and/or the registrations are
properly maintained, and the marks have not been found to have become generic.
ITEM 1A. | RISK FACTORS |
Risk Factors That May Affect Future Results
The risks and uncertainties described below are not the only risks and uncertainties the
Company faces. Additional risks and uncertainties not presently known to the Company or that are
currently deemed immaterial may also impair its business operations in a material way. If any of
the following risks actually occur, the Companys business, financial condition or results of
operations may suffer.
Our Operating Results May Fluctuate Due to Factors Outside of Managements Control
The Companys operating results may significantly fluctuate, and you should not rely on them
as an indication of the Companys future results. Future revenues and results of operations may
significantly fluctuate due to a combination of factors, many of which are outside of managements
control. The most notable of these factors include:
| vendor rebates; | ||
| seasonality; | ||
| the impact of economic factors on the national veterinary practices; | ||
| the timing and effectiveness of marketing programs offered by our vendors; | ||
| the timing of the introduction of new products and services; | ||
| exclusivity requirements with vendors that may prohibit distribution of competing products; | ||
| the recall of a significant product by one of our vendors; | ||
| extended shortage or backorder of a significant product by one of our vendors; | ||
| the timing and effectiveness of capital expenditures; | ||
| a disruption caused by adverse weather or other natural conditions; | ||
| inability to ship products to the customer as a result of technological or shipping disruptions; | ||
| changes in manufacturer contracts; and | ||
| competition. |
6
Any of the factors could adversely impact our results of operations and financial condition.
The Company may be unable to reduce operating expenses quickly enough to offset any unexpected
revenue shortfall. If the Company has a shortfall in revenue without a corresponding reduction to
its expenses, operating results may suffer.
The Market is Evolving, and If We Fail to Implement Our Business Plan, Our Profit May Be Negatively
Impacted.
Our revenues increased from $298.9 million in fiscal 2003 to $368.9 million in fiscal 2006.
Despite this period of rapid growth, our revenues have decreased in the past three years to $299.7
million in 2009. It may be difficult for us to increase our revenue and our future success depends
on our ability to implement and/or maintain:
| Sales and marketing programs; | ||
| Customer support programs; | ||
| Current and new product and service lines; | ||
| Technical support which equals or exceeds our competitors; | ||
| Vendor relationships; | ||
| Recruitment and training of new personnel; and | ||
| Operational and financial control systems. |
Our ability to successfully offer products and services and implement our business plan in an
evolving market requires an effective planning and management process. We expect that we will need
to continue to improve our financial and managerial controls and reporting systems and procedures
and to expand the training of our work force. If our revenues do not increase, and we increase our
services, our expenses may continue to increase resulting in additional periods of net loss.
Loss of Key Personnel Could Harm Our Business
Our future success depends to a significant extent on the skills, experience and efforts of
Company management and key members of its staff. The loss of any or all of these individuals could
damage our business. In addition, we must continue to develop and retain a core group of
individuals if we are to realize our goal of continued expansion and growth. We cannot assure you
that we will be able to do so.
Due to the specialized nature of our products and services, generally, only highly qualified
and trained individuals have the necessary skills to market our products and provide our services.
We face intense competition for the hiring of these professionals. Any failure on our part to hire,
train and retain a sufficient number of qualified professionals would damage our business.
There is No Market for Our Stock and the Value of the Stock Will Not Increase
There is no established public trading market for the Companys common stock. Sales are
limited to licensed veterinarians and veterinary clinics, and our common stock will not be sold,
assigned, or otherwise transferred to anyone other than the Company. The price of each share is
fixed at $3,000, or such lesser amount as determined by the Board of Directors in its discretion as
provided in our Articles of Incorporation and Bylaws. If a shareholder wishes to redeem his, her
or its share, the shareholder must sell it to the Company, and the Company may, but is not
obligated to purchase such share. If the Company elects to purchase the share, such shareholder
will receive only the amount he, she or it paid for the share.
We Rely on Strategic Relationships to Generate Revenue
To be successful, we must establish and maintain strategic relationships with leaders in the
manufacturing industry. This is critical to our success because we believe that these relationships
will enable us to:
| Extend the reach of our distribution and services to the various participants in the veterinary industry; | ||
| Obtain specialized expertise; and | ||
| Generate revenue. |
7
Entering into strategic relationships is complicated because some of our current manufacturers
may decide to compete with us in the future. In addition, we may not be able to establish
relationships with key participants in the veterinary distribution industry if we have established
relationships with competitors of such participants. Consequently, it is important that we are
perceived as independent of any particular customer or partner.
We do not have written agreements with all of our manufacturers, and some of our agreements
with manufacturers are not long-term and run for one year. We may not be able to renew our existing
agreements on favorable terms or at all. If we lose the right to distribute products under such
agreements, we may lose access to certain products and lose a competitive advantage. Potential
competitors could sell products from manufacturers that we fail to continue with and erode our
market share.
Performance or Security Problems With Our Systems Could Damage Our Business
Our information systems are dependent on third party software, global communications
providers, telephone systems and other aspects of technology and internet infrastructure that are
susceptible to failure. Though we have implemented redundant systems and security measures, our
customer satisfaction and our business could be harmed if we or our suppliers experience any system
delays, failures, loss of data, outages, computer viruses, break-ins or similar disruptions. We
currently process all customer transactions and data at our facilities in Omaha, Nebraska. Although
we have safeguards for emergencies, including, without limitation, sophisticated back-up systems,
the occurrence of a major catastrophic event or other system failure at either of our distribution
facilities could interrupt data processing or result in the loss of stored data. This may result in
the loss of customers or a reduction in demand for our services. Only some of our systems are fully
redundant and although we do carry business interruption insurance, it may not be sufficient to
compensate us for losses that may occur as a result of system failures. If disruption occurs, our
profitability and results of operations may suffer.
The outbreak of an infectious disease within either the production animal or companion animal
population could have a significant adverse effect on our business and our results of operations.
An outbreak of disease affecting animals, such as foot-and-mouth disease, avian
influenza or bovine spongiform encephalopathy, commonly referred to as mad cow disease, could
result in the widespread destruction of affected animals and consequently result in a reduction in
demand for animal health products. In addition, outbreaks of these or other diseases or concerns of
such diseases could create adverse publicity that may have a material adverse effect on consumer
demand for meat, dairy and poultry products, and, as a result, on our customers demand for the
products we distribute. The outbreak of a disease among the companion animal population which could
cause a reduction in the demand for companion animals could also adversely affect our business.
Although we have not been adversely impacted by the outbreak of a disease in the past, there can be
no assurance that a future outbreak of an infectious disease will not have an adverse effect on our
business.
We Face Significant Competition
The market for veterinary distribution services is intensely competitive, rapidly evolving and
subject to rapid technological change. We compete with numerous vendors and distributors based on
customer relationships, service and delivery, product selection, price and other capabilities. Some
of our competitors have more customers, stronger brand recognition or greater financial resources
than we do. Many of our competitors have comparable product lines, technical experience,
distribution strategies and financial resources. These organizations may be better known and have
more customers. We may be unable to compete successfully against these organizations.
Many of our competitors have distribution strategies that directly compete with us. We have
many competitors including Animal Health International, Inc., Butler Animal Health Supply, LLC,
Lextron Animal Health, Inc., MWI Veterinary Supply Co., Webster Veterinary Supply, IVESCO LLC and
other national, regional, local, and specialty distributors.
In addition, we expect that companies and others specializing in the veterinary products
industry will offer competitive products. Some of our large manufacturers/suppliers also may
compete with us through direct marketing and sales of their products. Increased competition could
result in price reductions, decreased revenue, and lower profit margins; loss of market share; and
increased marketing expectations. These and other competitive factors could materially and
adversely affect the Companys results of operations.
8
These factors affect our purchasing practices and operation of our business. Some of our
competitors are consolidating to create integrated delivery systems with greater market presence.
These competitors may try to use their market power to negotiate price reductions with the
manufacturers. If we were forced to reduce our prices, our operating results would suffer. As the
veterinary distribution industry consolidates, competition for customers will become more intense.
It is Unlikely We Will Pay Dividends
We have never declared or paid any cash dividends on our common stock. While our Articles of
Incorporation and Bylaws allow the payment of dividends, we currently intend to retain any future
earnings for funding the growth of our business and repayment of existing indebtedness, and
therefore, we do not currently anticipate declaring or paying cash dividends on our common stock in
the foreseeable future. In addition, our loan agreements restrict us from paying such dividends.
We May Not Be Able To Raise Needed Capital In the Future
To the extent that our existing sources of cash, plus any cash generated from operations, are
insufficient to fund our activities, we may need to raise or borrow additional funds. If we issue
additional stock to raise capital, your percentage of ownership in us would be reduced. Holders of
debt would have rights, preferences or privileges senior to those you possess as a holder of our
common stock. Additional financing may not be available when needed and, if such financing is
available, it may not be available on terms favorable to us. In addition, if we borrow money, we
will incur interest charges, which could negatively impact our profitability.
Our Substantial Leverage Could Harm Our Business By Limiting Our Available Cash and Our Access To
Additional Capital
As of July 31, 2009, our total long-term debt (excluding current portions) was approximately
$3.4 million, and we had $20.3 million outstanding under our revolving credit facility and an
additional $19.7 million of borrowing capacity available under such facility. Our degree of
leverage could have important consequences for you, including the following:
| it may limit our and our subsidiaries ability to obtain additional funds for working capital, capital expenditures, debt service requirements, or other purposes on favorable terms or at all; |
| a substantial portion of our cash flows from operations must be dedicated to the payment of principal and interest on our indebtedness and thus will not be available for other purposes, including operations, capital expenditures and future business opportunities; |
| it may limit our ability to adjust to changing market conditions and place us at a competitive disadvantage compared to those of our competitors that are less leveraged; |
| we may be more vulnerable than a less-leveraged company to a downturn in general economic conditions or in our business; or | ||
| we may be unable to carry out capital spending that is important to our growth. |
Our credit agreements contain covenants, among other things, that restrict our and our
subsidiaries ability to incur additional indebtedness; pay dividends or make other distributions;
make certain investments; use assets as security in other transactions; and sell certain assets or
merge with or into other companies. In addition, we are required to satisfy and maintain specified
financial ratios and tests. Events beyond our control may affect our ability to comply with these
provisions, and we or our subsidiaries may not be able to meet those ratios and tests. The breach
of any of these covenants would result in a default under our credit agreement and the lender could
elect to declare all amounts borrowed under the applicable agreement, together with accrued
interest, to be due and payable and could proceed against the collateral securing that
indebtedness. If any of our indebtedness were to be accelerated, our assets may not be sufficient
to repay in full that indebtedness. For the fiscal year ended
July 31, 2009 the Company was in violation of certain of these
covenants for which a waiver of non-compliance was received from the
lender.
Our Variable Rate Indebtedness Subjects Us To Interest Rate Risk, Which Could Cause Our Debt
Service Obligations To Increase Significantly
Certain of our borrowings, primarily borrowings under our revolving line of credit, are at
variable rates of interest and expose us to interest rate risk based on market rates. If interest
rates increase, our debt service obligations on the variable rate indebtedness would increase even
though the amount borrowed remained the same,
9
and our net income and cash available for servicing our indebtedness would decrease. Our
variable rate debt for the year ended July 31, 2009 was approximately $20.3 million with related
interest expense of $0.6 million. A 1% increase in the average interest rate would increase future
interest expense by approximately $235 thousand per year assuming an average outstanding balance
under the revolving line of credit of $23.5 million.
We Rely Substantially On Third-Party Suppliers, and the Loss Of Products or Delays In Product
Availability From One Or More Third-Party Suppliers Could Substantially Harm Our Business
We must contract for the supply of current and future products of appropriate quantity,
quality and cost. Such products must be available on a timely basis and be in compliance with any
regulatory requirements. Failure to do so could substantially harm our business.
We often purchase products from our suppliers under agreements that are of limited duration or
can be terminated on a periodic basis. There can be no assurance, however, that our suppliers will
be able to meet their obligations under these agreements or that we will be able to compel them to
do so. Risks of relying on suppliers include:
| If an existing agreement expires or a certain product line is discontinued, then we would not be able to continue to offer our customers the same breadth of products and our sales and operating results would likely suffer unless we are able to find an alternate supply of a similar product. |
| Current agreements, or agreements we may negotiate in the future, may commit us to certain minimum purchase or other spending obligations. It is possible we will not be able to create the market demand to meet such obligations, which would create an increased drain on our financial resources and liquidity. |
| If market demand for our products increases suddenly, our current suppliers might not be able to fulfill our commercial needs, which would require us to seek new manufacturing arrangements or new sources of supply and may result in substantial delays in meeting market demand. If we consistently generate more demand for a product than a given supplier is capable of handling, it could lead to large backorders and potentially lost sales to competitive products that are readily available. This also could require us to seek new sources of supplies. |
| We may not be able to control or adequately monitor the quality of products we receive from our suppliers. Poor quality products could damage our reputation with our customers. |
| Some of our third party suppliers are subject to ongoing periodic unannounced inspection by regulatory authorities, including the FDA, DEA, Environmental Protection Agency (EPA) and other federal and state agencies for compliance with strictly enforced regulations, and we do not have control over our suppliers compliance with these regulations and standards. Violations could potentially lead to interruptions in supply that could cause us to lose sales to readily available competitive products. |
| If any of our vendors is unable to obtain the necessary credit to manage its business, it may not be able to deliver its products to us. |
Potential problems with suppliers such as those discussed above could substantially decrease
sales, lead to higher costs and damage our reputation with our customers due to factors such as
poor quality goods or delays in order fulfillment, which may result in decreased sales of our
products and substantially harm our business.
We Rely Upon Third Parties to Ship Products to Our Customers and Interruptions in Their Operations
Could Harm Our Business, Financial Condition and Results of Operations
We use UPS and FedEx as our primary delivery services for our air and ground shipments of
products to our customers. If there were any significant service interruptions, there can be no
assurance that we could engage alternative service providers to deliver these products in either a
timely or cost-efficient manner, particularly in rural areas where many of our customers are
located. Any strikes, slowdowns, transportation disruptions or other adverse conditions in the
transportation industry experienced by any of our delivery services could impair or disrupt our
ability to deliver our products to our customers on a timely basis and could have a material
adverse effect upon our customer relationships, business, financial condition and results of
operations. In addition, any increase in the shipping costs, including fuel surcharge, could have
an adverse effect on our financial condition and results of operations.
10
We Are Exposed To Potential Risks From Legislation Requiring Companies To Evaluate Controls Under
Section 404 Of The Sarbanes-Oxley Act Of 2002
We have evaluated and tested our internal controls in order to allow management to report on
and attest to, our internal controls, as required by Section 404 of the Sarbanes-Oxley Act of 2002
(Section 404). We have incurred, and expect to incur expenses and a diversion of managements
time to meet the requirements of Section 404. If we are not able to continue to meet the
requirements of Section 404 in a timely manner or with adequate compliance, we might be required to
disclose material weaknesses if they develop or are uncovered and we may be subject to sanctions or
investigation by regulatory authorities, such as the Securities and Exchange Commission. Any such
action could negatively impact the perception of the Company and our business. In addition, our
internal controls may not prevent or detect all error and fraud. A control system, no matter how
well designed and operated, is based upon certain assumptions and can provide only reasonable
assurance that the objectives of the control system will be met. Our registered independent public
accounting firm is required to attest to our internal controls, as required by Section 404, for our
fiscal year ending July 31, 2010.
Changes in the Veterinary Distribution Industry Could Adversely Affect Our Business
The veterinary distribution industry is subject to changing political, economic and regulatory
influences. Both state and federal government agencies regulate the distribution of certain animal
health products and the Company is subject to regulation, either directly or indirectly, by the
USDA, the FDA and the DEA. To the extent the political party in power changes, whether in the
executive or legislative branch, the regulatory stance these agencies take could change. Our
suppliers are subject to regulation by the USDA, the FDA, the DEA, and the EPA, and material
changes to the applicable regulations could affect the suppliers ability to manufacture certain
products which could adversely impact the Companys product supply. In addition, some of our
customers may rely, in part, on farm and agricultural subsidy programs. Changes in the regulatory
positions that impact the availability of funding of such programs could have an adverse impact on
our customers financial position which could lead to decreased sales.
These factors affect our purchasing practices and operations of our business. Some of our
competitors are consolidating to create integrated delivery systems with greater market presence.
These competitors may try to use their market power to negotiate price reductions with the
manufacturers. If we were forced to reduce our prices, our operating results would suffer. As the
veterinary distribution industry consolidates, competition for customers will become more intense.
Consolidation in the Veterinary Distribution Business and Veterinary Practices May Decrease Our
Revenues and Profitability
The consolidation in the veterinary distribution business could result in existing competitors
increasing their market share. This could lead to greater pricing power, decrease our Companys
revenues and profitability, and increase the competition for our customers. Consolidation of the
small, privately-held veterinary practices could result in an increasing number of larger
veterinary practices, which could have increased purchasing leverage and the ability to negotiate
lower product costs. This could reduce our operating margins and negatively impact our revenues
and profitability. Any of these developments could result in increased marketing expenses and have
a material adverse effect on our business, financial condition and results of operations.
Consolidation Among Animal Health Product Vendors may Decrease our Sales and Profitability
On January 26, 2009, Pfizer announced that it had entered into an agreement to acquire all of
the outstanding stock of Wyeth. Pfizer and Fort Dodge, a division of Wyeth, accounted for
approximately 40.6% and 7.2%, respectively of our purchases during the twelve months ended July 31,
2009. On March 9, 2009, Merck announced that it had entered into an agreement to acquire all of
the outstanding stock of Schering-Plough. Merial Limited, a joint venture between Merck & Co.,
Inc. and Sanofi Aventis S.A., and Intervet-Schering, a subsidiary of Schering-Plough, accounted for
approximately 3.6% and 11.6%, respectively of our purchases during the twelve months ended July 31,
2009. Consolidation among animal health products vendors could result in our vendors increasing
their market share, which could give greater pricing power and make it easier for such vendors to
sell their products directly to animal health customers, both of which could decrease our net sales
and profitability. Finally, if our current vendors consolidate, their management teams are more
likely to change, which could result in adverse changes in distribution practices.
11
The General Economic Downturn may Adversely Affect our Business
A deepening or protraction of the general economic downturn could increase volatility in feed
and animal protein commodity prices, reduce or eliminate sources of credit available to our
customers, as well as reduce consumer discretionary spending on animal health products. Such
volatility and/or tightening of credit could further deteriorate the financial condition of our
customers, and may ultimately lead our customers to reduce their working capital. As a result, we
may experience reduced demand for our products and services, and may be unable to collect amounts
owed, each of which could materially impact our results of operations.
Exclusivity Requirements and Failures to Continue Relationships With Vendors May Cause Us to Lose
Access to Certain Products and Erode Our Market Share
We may not be able to establish or maintain our relationships with key vendors in the animal
health industry if we have established relationships with competitors of these key vendors. We
have written agreements with many of our vendors, including Pfizer. Some of our agreements with
our vendors are for one-year periods. Upon expiration, we may not be able to renew our existing
agreements on favorable terms, or at all.
In addition, during our course of negotiation of these agreements, certain vendors may require
us to distribute their products on an exclusive basis which could cause us to forego distributing
competing products that may also be profitable. In this situation the Company may be forced to
project future sales of competing products so that we can elect to distribute the product that we
believe will be more profitable. The Companys projections may not be accurate, and we may be
contractually prohibited from distributing products that gain market share at the expense of the
products that we distribute. Competitors of ours could also obtain exclusive rights to market
particular products which we would be unable to market. If we lose the right to distribute
products under such agreements, or are required to exclusively distribute certain products at the
expense of others that may be more profitable, we may lose access to certain products and lose a
competitive advantage. Potential competitors could sell products from vendors that we fail to
continue with and erode our market share.
Our Business, Financial Condition And Results of Operations Depend Upon Maintaining Our
Relationships With Vendors
We currently distribute more than 20,000 products sourced from more than 300 vendors. We
currently do not manufacture any of our products and are dependent on these vendors for our supply
of products. Our top two vendors, Pfizer, and Intervet-Schering, a subsidiary of Schering Plough
supplied products that accounted for approximately 52.2% of our product purchases for the fiscal
year ended July 31, 2009.
Our ability to sustain our gross profits has been, and will continue to be, dependent in part
upon our ability to obtain favorable terms and access to new and existing products from our
vendors. These terms may be subject to changes from time to time by vendors, such as changing from
a buy/sell to an agency relationship, or from an agency to a buy/sell relationship. In a
buy/sell transaction, we purchase or take inventory of products from our vendors. Under an agency
relationship, when we receive orders for products from a customer, we transmit the order to the
vendor who then picks, packs and ships the products. Any changes from buy/sell to agency or from
agency to buy/sell could adversely affect our revenues and operating income. The loss of one or
more of our large vendors, a material reduction in their supply of products or material changes in
the terms we obtain from them could have a material adverse effect on our business, financial
condition and results of operations.
Some of our current and future vendors may decide to compete with us in the future by pursuing
or increasing their efforts in direct marketing and sales of their products. These vendors could
sell their products at lower prices and maintain a higher gross margin on their product sales than
we can. In this event, veterinarians or animal owners may elect to purchase animal health products
directly from these vendors. Increased competition from any vendor of animal health products could
significantly reduce our market share and adversely impact our financial results.
In addition, we may not be able to establish relationships with key vendors in the animal
health industry if we have established relationships with competitors of these key vendors. We have
written agreements with several of our vendors. Some of our agreements with vendors are for
one-year periods. Upon expiration, we may not be able to renew our existing agreements on favorable
terms, or at all. If we lose the right to distribute products under such agreements, we may lose
access to certain products and lose a competitive advantage. Potential competitors could sell
products from vendors that we fail to continue with and erode our market share.
An Adverse Change in Vendor Rebates Could Negatively Affect Our Results of Operation
The terms under which we purchase animal health products from several vendors entitle us to
receive a rebate based upon the attainment of certain growth goals. If market conditions
deteriorate or other factors outside of
12
our control change, vendors may adversely change the terms of some or all of these rebate
programs and there can be no assurance as to the amount of rebates that we will receive in any
given year. The occurrence of any of these events could have an adverse impact on our results of
operations, and as a result, you may not receive a rebate under our annual program.
Our Quarterly Operating Results May Fluctuate Significantly
Our quarterly revenues and operating results have varied significantly in the past and may
continue to do so in the future. Rebates received from vendors have historically been the greatest
during the quarter ending January 31. The timing of the receipt of our revenues is directly tied to
the buying patterns of veterinarians related to certain medical procedures performed on production
animals during the spring and fall months. These buying patterns also can be affected by vendors
and distributors marketing programs launched during the summer months, which can result in
veterinarians purchasing products earlier than they are needed. This kind of early purchasing may
reduce our sales in the months these purchases would have otherwise been made.
If We Fail to Comply With or Become Subject to More Onerous Government Regulations, Our Business
Could be Adversely Affected
The veterinary distribution industry is subject to changing political, economic and regulatory
influences. Both state and federal government agencies regulate the distribution of certain animal
health products, and the Company is subject to regulation, either directly or indirectly, by the
USDA, the FDA, the EPA, and the DEA and state boards of pharmacy. The regulatory stance these
agencies take could change. Our suppliers are subject to regulation by the USDA, the FDA, the DEA,
and the EPA, and material changes to the applicable regulations could affect the suppliers ability
to manufacture certain products which could adversely impact the Companys product supply. In
addition, some of our customers may rely, in part, on farm and agricultural subsidy programs.
Changes in the regulatory positions that impact the availability of funding for such programs could
have an adverse impact on our customers financial positions which could lead to decreased sales.
Effective December 1, 2006, the federal drug pedigree requirements of the FDA under the
Prescription Drug Marketing Act (PDMA) went into effect. Although a court injunction was granted
regarding some provisions, the FDA mandated that all distributors that are not the manufacturers
authorized distributor must provide a record of all previous transactions. This transaction history
is also referred to as a pedigree. The federal pedigree regulations require tracking human labeled
prescription products through the entire distribution chain and are enforceable for distributors
that do not have a written agreement with the manufacturer granting the wholesale distributor
status as an Authorized Distributor of Record. We strive to maintain compliance with the new
pedigree requirements and other laws and regulations. However, if we are unable to maintain our
active compliance with these laws and regulations, we could be subject to substantial fines or
other restrictions on our ability to provide competitive distribution services, which could have an
adverse impact on our financial condition.
We cannot assure you that existing laws and regulations will not be revised or that new, more
restrictive laws will not be adopted or become applicable to us or the products that we distribute
or dispense. We cannot assure you that the vendors of products that may become subject to more
stringent laws will not try to recover any or all increased costs of compliance from us by
increasing the prices at which we purchase products from them, or, that we will be able to recover
any such increased prices from our customers. We also cannot assure you that our business and
financial condition will not be materially and adversely affected by future changes in applicable
laws and regulations.
ITEM 1B. | UNRESOLVED STAFF COMMENTS |
None.
ITEM 2. | PROPERTIES |
Headquarters in Omaha, Nebraska
The Company owns a building that serves as its corporate headquarters and is nearly 100,000
square feet of open warehouse space and 40,000 square feet of finished office area. The building is
a facility the Company constructed and completed in late 1999 and is located on 9.6 acres of land
in a newly developed industrial subdivision of Omaha, Nebraska. The building and the land is
subject to a first mortgage held by First National Bank of Omaha. In October 2002 the Company
purchased 10 acres of land adjacent to the current corporate facility
13
in Omaha, Nebraska for approximately $808 thousand in order to provide the Company with land
available for future expansion of its Omaha facility.
York, Pennsylvania
On March 15, 2002, the Company signed a lease agreement with Kinsley Equities II Limited
Partnership for 70,000 square feet of warehouse space in York, Pennsylvania. The initial term of
the lease was five years. The Company uses this facility to ship products to its customers in that
geographical area of the United States. In June 2003, the Company exercised an option to lease an
additional 17,500 square feet of space in the York facility for a total of 87,500 square feet of
leased space. In January 2007, the Company and Kinsley Equities II Limited Partnership extended
the lease term from July 31, 2007 to July 31, 2010.
Quincy, Illinois
On May 1, 2009, the Company signed a lease agreement with Wiemelt Properties for 21,875 square
feet of warehouse space in Quincy, Illinois. The initial term of the lease is one year with the
option for additional years. The Company uses this facility to ship predominantly products for
treatment and/or prevention of diseases in food animals to its customers in that geographical area
of the United States.
Mankato, Minnesota
On May 1, 2009, the Company signed a lease agreement with Atlas Alchem Plastics, Inc. for
36,135 square feet of warehouse space in Mankato, Minnesota. The initial term of the lease is six
months. The Company uses this facility to ship predominantly products for treatment and/or
prevention of diseases in food animals to its customers in that geographical area of the United
States.
Spicer, Minnesota
One June 1, 2009, the Company signed a lease agreement with Brad Kelley for 9,000 square feet
of warehouse space in Spicer, Minnesota. The initial term of the lease is six months. The Company
uses this facility to ship predominantly products for treatment and/or prevention of diseases in
food animals to its customers in that geographical area of the United States.
Management believes that our existing facilities are and will be adequate for the conduct of
our business during the next fiscal year.
ITEM 3. | LEGAL PROCEEDINGS |
On April 7, 2009, IVESCO Holdings, LLC (IVESCO) filed a lawsuit in the United States District
Court for the Northern District of Iowa, Case No. 1:09CV52, against the Company and its wholly
owned subsidiary, ProConn LLC (ProConn). IVESCO alleges that the Company conspired with certain
departing IVESCO employees to take over or steal the IVESCO swine business through the
simultaneous departure of most of the employees in the swine division. IVESCO also alleges a
conspiracy to unfairly compete, tortious interference with business expectancies between IVESCO and
its customers and employee relationships, aiding and abetting an alleged breach of duty by former
IVESCO employees, and unjust enrichment by the receipt of sales revenue without payment of fair
value. IVESCO seeks damages in an unstated amount, the imposition of a constructive trust upon
earnings of the Companys swine product sales, restitution by disgorgement of profits, interest,
punitive damages, costs and attorney fees. The Company has filed a responsive pleading denying the
allegations and intends to vigorously defend against IVESCOs claims.
In addition to IVESCO litigation, the Company is subject to claims and other actions arising
in the ordinary course of business. Some of these claims and actions may result in lawsuits where
the Company is a defendant. Management believes that the ultimate obligations, if any, which may
result from unfavorable outcomes of such lawsuits, will not have a material adverse effect on the
financial position, results of operations or cash flows of the Company and such obligations, if
any, would be adequately covered by insurance.
ITEM 4. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
No matters were submitted to a vote of security holders during the quarter ended July 31,
2009.
14
PART II
ITEM 5. | MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES |
There is no established public trading market for the Companys common stock. Ownership of the
Companys stock is limited to licensed, practicing veterinarians or any entity established to
deliver veterinary services and/or products in which all medical decisions are made by licensed
veterinarians (such as a partnership or corporation). Each veterinarian shareholder is limited to
ownership of one share of stock, which is purchased at the fixed price of $3,000. The share of
stock may not be sold, assigned, or otherwise transferred, except back to the Company at the same
$3,000 price. On September 30, 2009, there were 1936 record holders of the Companys common stock.
Shareholders have no preemptive rights or rights to convert their common stock into any other
securities. There are no redemption or sinking fund provisions applicable to the common stock other
than optional redemption by the Company set forth in the Articles of Incorporation and Bylaws. The
Company does not have any preferred stock authorized and has not issued any stock options, stock
option plans, warrants, or other outstanding rights or entitlements to common stock.
The Company has never declared or paid any cash dividends on the common stock. The Company
intends to retain any future earnings for funding growth of the Companys business and therefore
does not currently anticipate paying cash dividends in the foreseeable future. The Company has not
sold any common stock which was not registered under the Securities Act of 1933 within the past
three fiscal years ended July 31, 2009.
Under its Articles of Incorporation, the Company may repurchase shares of any shareholder who
is no longer a veterinarian or veterinary clinic or owes money to the Company and fails to make
required payments. The Company may, but is not obligated to repurchase the stock. The redemption
amount is the original purchase price of the stock paid by the shareholder. There is no expiration
date for repurchase. Since the Companys inception, each shareholder has been entitled to request
that his, her, or its share be redeemed in accordance with the Articles of Incorporation and
Bylaws.
During the fourth quarter ended July 31, 2009, the Company repurchased sixteen (16) shares of
its common stock as set forth in the following table:
Purchases of Equity Securities by the Company and Affiliated Purchasers:
Total Number of | Maximum | |||||||||||||||
Shares | Number of | |||||||||||||||
Purchased as | Shares That | |||||||||||||||
Part of Publicly | May Yet Be | |||||||||||||||
Total Number | Announced | Purchased | ||||||||||||||
of Shares | Average Price | Plans or | Under the Plans | |||||||||||||
Period | Purchased | Paid Per Share | Programs | or Programs(1) | ||||||||||||
May 1 May 31, 2009 |
6 | $ | 3,000 | | 1,958 | |||||||||||
June 1 June 30, 2009 |
8 | $ | 3,000 | | 1,950 | |||||||||||
July 1 July 31, 2009 |
2 | $ | 3,000 | | 1,948 | |||||||||||
Total: |
16 | $ | 3,000 | | 1,948 |
(1) | The maximum number of shares that may be purchased by the Company varies from time to time due to the on-going redemption of shares. |
15
ITEM 6. | SELECTED FINANCIAL DATA |
The following table presents selected financial data for the Company for each of the five
years ended July 31, 2009. The historical selected financial data are derived from the Companys
Financial Statements included elsewhere in this report and should be read in conjunction with those
financial statements and notes thereto. All amounts are in thousands except per share data.
2005 | 2006 | 2007 | 2008 | 2009 | ||||||||||||||||
Net sales and other revenues |
$ | 387,249 | $ | 368,926 | $ | 342,699 | $ | 339,838 | $ | 299,729 | ||||||||||
Operating income (loss) |
$ | 4,610 | $ | 5,089 | $ | 5,500 | $ | 3,808 | $ | (6,409 | ) | |||||||||
Net income (loss) |
$ | 2,536 | $ | 2,392 | $ | 2,384 | $ | 1,428 | $ | (4,373 | ) | |||||||||
Income per share: |
||||||||||||||||||||
Operating income (loss) |
$ | 3,677 | $ | 3,612 | $ | 2,697 | $ | 1,861 | $ | (3,227 | ) | |||||||||
Net income (loss) |
$ | 2,023 | $ | 1,698 | $ | 1,169 | $ | 698 | $ | (2,202 | ) | |||||||||
Redeemable common shares
outstanding used in the
calculation |
1,254 | | | | | |||||||||||||||
Common shares outstanding
used in the calculation |
| 1,409 | 2,039 | 2,046 | 1,986 | |||||||||||||||
Total assets |
$ | 85,266 | $ | 76,399 | $ | 88,244 | $ | 81,194 | $ | 79,733 | ||||||||||
Total long-term obligations |
$ | 5,109 | $ | 5,375 | $ | 6,761 | $ | 6,620 | $ | 6,181 | ||||||||||
Total number of shares
subject to mandatory
redemption(1) |
731 | | | | | |||||||||||||||
Total number of common shares |
| 2,042 | 2,068 | 2,037 | 1,948 | |||||||||||||||
Total number of redeemable
common shares(1) |
1,288 | | | | |
(1) | For additional information on the Companys shares, see Note 5 to the 2009 Consolidated Financial Statements. |
16
ITEM 7. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The following discussion and analysis of the Companys financial condition and results of
operations should be read in conjunction with the consolidated financial statements and
accompanying notes that are included in this annual report.
Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements. Forward-looking
statements are contained principally in the sections entitled Business, Risk Factors and
Managements Discussion and Analysis of Financial Condition and Results of Operations. These
statements involve known and unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements to be materially different from any future results,
performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements include, but are not limited to, statements about:
| the current economic environment affecting the Company and the markets it serves; | ||
| sources of revenues and anticipated revenues, including the contribution from the growth of new products and markets; |
| estimates regarding the Companys capital requirements and its need for additional financing; | ||
| the Companys ability to attract customers and the market acceptance of its products; | ||
| our ability to establish relationships with suppliers of products; and | ||
| plans for future products and services and for enhancements of existing products and services. |
In some cases, you can identify forward-looking statements by terms such as may, intend,
might, will, should, could, would, expect, believe, estimate, predict,
potential, or the negative of these terms, and similar expressions intended to identify
forward-looking statements. These statements reflect our current views with respect to future
events and are based on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these statements. We discuss many of these
risks in this Annual Report on Form 10-K in greater detail under the heading Risk Factors. Also,
these statements represent our estimates and assumptions only as of the date of this Annual Report
on Form 10-K, and we undertake no obligation to publicly update or revise these forward-looking
statements.
Overview
Professional Veterinary Products, Ltd. provides distribution services of animal health
products through three business segments: Wholesale Distribution, Logistics Services, and Direct
Customer Services. The Wholesale Distribution segment is a wholesaler of animal health products.
The Logistics Services segment provides logistics and distribution service operations for animal
health vendors in business-to-business type transactions. The Direct Customer Services segment is a
supplier of animal health products to the producer or consumer.
The Companys Wholesale Distribution segment comprises the majority of its operations,
representing approximately 81% of net sales and other revenue in fiscal 2009. Revenues are
primarily earned by distributing products to veterinarians or veterinary practices. The main factor
that impacts net sales is the Companys ability to offer a broad product line through excellent and
knowledgeable customer service. For 2009, the Direct Customer Services segment represented
approximately 19% of net sales and other revenues.
The Companys revenues increased from $298.9 million in fiscal year 2003 to $368.9 million in
fiscal year 2006, an increase of 23%. In fiscal year 2007, revenues decreased by $26.2 million to
$342.7 million, (a decrease of 7%) in fiscal year 2008, decreased further by $2.9 million to $339.8
million (a decrease of less than 1%), and in fiscal year 2009, decreased further by $40.1 million
to $299.7 million, a decrease of 12%. The decrease in 2009 is primarily due to a decrease in
vendor sales, purchase incentives and an increase in sales discounts to customers. The Company
distributes a majority of its products to shareholders but over time has increased its sales to
non-shareholders. In fiscal year 2009, net sales and other revenue to shareholders totaled $199.4
million or 66% of total consolidated net sales and other revenue. The Companys long-term strategy
is to utilize competitive pricing with
17
operational efficiencies to compete in todays marketplace. To further this strategy, the
Company is developing a pricing strategy with forecasting and predictive modeling capabilities,
which the Company anticipates will allow it to respond to the continually changing market
conditions.
The Company has historically provided annual rebates to its shareholders. In fiscal 2007, the
rebates were approximately $3.0 million. In fiscal 2008, management determined that no rebate
would be issued and that it was in the Companys best interest to retain net income for on-going
business needs, rather than shareholder rebates. In fiscal 2009, the rebates were approximately
$0.7 million.
We believe that there is likely to be consolidation of the many small privately owned
veterinary clinics, which will result in an increasing number of larger veterinary practice
business units. As a result, we expect that the larger veterinary practices will have increased
purchasing leverage and will negotiate for lower product costs which will reduce margins at the
distribution level and impact Company revenue and net income.
Current Assets
Current assets decreased by $0.6 million to $67.6 million for fiscal year 2009 compared to
$68.2 million for the previous year. This decrease was primarily due to a decrease in accounts
receivable of $3.9 million which resulted from an increase in cash receipts from customers.
Offsetting this decrease was an increase in inventory of $1.2 million and prepaid expenses of $2.6
million. The increase in inventory resulted from the Companys purchase of additional products from
vendors.
Current Liabilities
Current liabilities increased by $3.6 million to $54.6 million for fiscal year 2009 compared
to $51.0 million for the previous year. This increase was primarily due to an increase of $7.4
million of borrowings under the line of credit to fund operations. Offsetting this increase was a
decrease in accounts payable of $3.7 million.
Results of Operations
The following discussion is based on the historical results of operations for fiscal 2008,
2007 and 2006.
Summary Consolidated Results of Operations Table
July 31, 2009 | July 31, 2008 | July 31, 2007 | ||||||||||
(In Thousands) | ||||||||||||
Net sales and other revenue |
$ | 299,729 | $ | 339,838 | $ | 342,699 | ||||||
Cost of sales |
266,334 | 295,596 | 301,122 | |||||||||
Gross profit |
33,395 | 44,242 | 41,577 | |||||||||
Operating, general and administrative
expenses |
39,804 | 40,434 | 36,077 | |||||||||
Operating income (loss) |
(6,409 | ) | 3,808 | 5,500 | ||||||||
Interest expense, net |
(735 | ) | (1,061 | ) | (1,676 | ) | ||||||
Equity in earnings of unconsolidated affiliate |
| 53 | 116 | |||||||||
Loss on the sale of unconsolidated affiliate |
| (571 | ) | | ||||||||
Other income (expense) |
| 1 | (81 | ) | ||||||||
Income (loss) before taxes |
(7,144 | ) | 2,230 | 3,859 | ||||||||
Income tax expense (benefit) |
(2,771 | ) | 802 | 1,475 | ||||||||
Net income (loss) |
$ | (4,373 | ) | $ | 1,428 | $ | 2,384 | |||||
Beginning retained earnings |
17,935 | 16,507 | 14,123 | |||||||||
Ending retained earnings |
$ | 13,562 | $ | 17,935 | $ | 16,507 | ||||||
Net sales and other revenue were $299.7 million in 2009, $339.8 million in 2008 and $342.7
million in 2007. The decrease in net sales and other revenue in 2009 over 2008 resulted primarily
from a decrease in sales to
18
existing customers of $22.7 million, an increase in sales discounts to customers of $2.4
million, and an increase in the shareholder rebate of $0.7 million. For the purpose of calculating
revenue growth rates of new and existing customers, the Company has defined a new customer as a
customer that did not purchase product from the Company in the corresponding prior fiscal year,
with the remaining customer base being considered an existing customer. Of this decrease, $32.5
million resulted from the termination of the logistical services agreement with SERVCO effective
June 30, 2008. Partially offsetting this decrease were increases in sales to new customers of
$18.2 million. No rebate was paid in fiscal 2008, compared to rebate of $0.7 million issued in
fiscal 2009. The rebate, if any, is netted against sales and accounts receivable on the Companys
financial statements.
The decrease in net sales and other revenue in 2008 over 2007 resulted primarily from a
decrease in sales to existing customers of $12.8 million. Of this decrease, $4.3 million resulted
from the termination of the logistical services agreement with SERVCO. Partially offsetting this
decrease were increases in sales to new customers of $6.1 million and in agency commission of $0.8
million. No rebate was paid in fiscal 2008, compared to rebate of $3.0 million issued in fiscal
2007.
Cost of sales were $266.3 million in 2009, $295.6 million in 2008 and $301.1 million in 2007.
The decrease in cost of sales in 2009 over 2008 resulted primarily from a decrease in cost of goods
sold of $34.2 million and a decrease in freight expense of $1.5 million. Partially offsetting this
decrease was a decrease in vendor sales and purchase incentives of $6.4 million. The cost of sales
sold includes the Companys inventory product cost and freight costs less vendor purchase and sales
incentives. Vendor sales and purchase incentives are recorded based on the terms of the contracts
or programs with each vendor. Vendor sales and purchase incentives are classified in the
accompanying consolidated statements of income as a reduction to cost of sales sold at the time of
the performance measures are achieved. The decrease in cost of sales in 2008 over 2007 resulted
primarily from a decrease in cost of goods sold of $5.5 million and an increase in vendor sales and
purchase incentives of $2.7 million. Partially offsetting this decrease was an increase in freight
expense of $2.8 million.
Gross profit was $33.4 million in 2009, $44.2 million in 2008 and $41.6 million in 2007. The
decrease in gross profit in 2009 over 2008 resulted primarily from a decrease in vendor sales and
purchase incentives of $6.4 million and an increase in sales discounts to customers of $2.4
million. The increase in gross profit in 2008 over 2007 resulted primarily from an increase in
vendor sales and purchase incentives of $2.7 million.
Operating, general and administrative expenses were $39.8 million in 2009, $40.4 million in
2008 and $36.1 million in 2007. The decrease in operating, general and administrative expenses in
2009 over 2008 resulted from decreases in the following: payroll, payroll taxes, and employee
benefits of $0.8 million, profit sharing of $0.1 million, directors fees and expense of $0.1
million, vet of record commission of $0.2 million, commission royalty expense of $0.1 million,
employee education of $0.4 million, communication expense of $0.2 million, and operating supplies
and expense of $0.1 million. Partially offsetting these decreases were increases in the following:
pharmacy fees of $0.2 million, computer supplies and support expense of $0.9 million, and bad debt
expense of $0.3 million. The increases in computer supplies and support expenses resulted from the
Companys investment in technology to increase value to our customers and to the Company. Although
operating, general and administrative expenses decreased during 2009, these expenses, as percentage
of net sales, were 10.5% in 2007 and increased to 11.9% and 13.3% in 2008 and 2009, respectively.
The increase in operating, general and administrative expenses in 2008 over 2007 resulted primarily
from an increase in the following: payroll, payroll taxes, and employee benefits of $1.6 million,
computer supplies and support expense of $0.9 million, professional services of $0.9 million,
employee reimbursed expenses of $0.3 million, depreciation expense $0.3 million, directors fees
and expenses of $0.1 million, employee education of $0.1 million, communication expense of $0.1
million, and credit card fees of $0.1 million. The increases in operating, general and
administrative expenses resulted from the Companys investment in technology to increase value to
our customers and to the Company.
Operating income (loss) was $(6.4) million in 2009, $3.8 million in 2008 and $5.5 million in
2007. The decrease in operating income in 2009 over 2008 resulted primarily from a decrease in
gross profit margin of $10.8 million. Offsetting this decrease was a decrease in operating,
general and administrative expenses of $0.6 million. The decrease in operating income in 2008 over
2007 resulted primarily from an increase in operating, general and administrative expenses of $4.4
million. Offsetting this decrease was an increase in gross profit margin of $2.7 million.
The Companys other income and interest (expense) was $(0.7) million in 2009, $(1.6) million
in 2008 and $(1.6) million in 2007. The Companys other income and interest (expense) in 2008 over
2007 remained unchanged. The decrease in interest (expense) in 2009 over 2008 resulted primarily
from a decrease in interest expense of $0.3 million which was due to a lower average interest rate
in the period on outstanding debt. The increase in interest income in 2009 over 2008 resulted
primarily from an increase in interest income of $0.04 million, which was a
19
result of finance charges on past due accounts receivable. The sale of the SERVCO stock on
July 14, 2008 resulted in a decrease in equity earnings of unconsolidated affiliates of $0.06
million in 2008 and an increase in the (loss) on the sale of unconsolidated affiliate of $0.6
million. The decrease in interest (expense) in 2008 over 2007 resulted primarily from a decrease
in interest expense of $0.6 million which was due to a lower average interest rate in the period on
outstanding debt. The increase in interest income in 2008 over 2007 resulted primarily from an
increase in interest income of $0.06 million, which was a result of finance charges on past due
accounts receivable. The sale of the SERVCO stock on July 14, 2008 resulted in a decrease in
equity earnings of unconsolidated affiliates of $0.06 million in 2008 and an increase in the (loss)
on the sale of unconsolidated affiliate of $0.6 million.
Contractual Obligations and Commitments
The Companys contractual obligations (in thousands) at July 31, 2009 mature as follows:
PAYMENTS DUE BY PERIOD | ||||||||||||||||||||
Less than 1 | More than 5 | |||||||||||||||||||
Total | Year | 1-2 Years | 3-5 Years | Years | ||||||||||||||||
Loans payable to banks |
$ | 20,287 | $ | 20,287 | $ | | $ | | $ | | ||||||||||
Operating lease commitments |
1,881 | 1,047 | 657 | 177 | | |||||||||||||||
Supplemental Executive
Retirement Plan |
2,427 | 243 | 486 | 729 | 969 | |||||||||||||||
Long-term debt obligations (including
current portion)(1) |
3,770 | 400 | 893 | 1,034 | 1,443 | |||||||||||||||
Total contractual obligations(2) |
$ | 28,365 | $ | 21,977 | $ | 2,036 | $ | 1,940 | $ | 2,412 | ||||||||||
(1) | Interest payments due on long-term debt for less than 1 year are $284 thousand, 1-2 years are $428 thousand, 3-5 years are $554 thousand, and after 5 years are $107 thousand. | |
(2) | See Notes 7 and 10 of the Consolidated Financial Statements for additional information. |
The Companys Bylaws allow the Company to repurchase stock upon receipt of written notice from
a shareholder requesting redemption of his, her, or its stock. The Company may, but is not
obligated to repurchase the stock. The redemption amount is the original purchase price of the
stock paid by the shareholder.
Operating Segments
The Company has three reportable segments: Wholesale Distribution, Logistics Services, and
Direct Customer Services. The Wholesale Distribution segment is a wholesaler of animal health
products. This segment distributes products primarily to licensed veterinarians or business
entities comprised of licensed veterinarians.
The Logistics Services segment provides logistics and distribution service operations for
animal health vendors in business-to-business type transactions. The Logistics Services segment
distributes products primarily to other animal health companies.
The Direct Customer Services segment is a supplier of animal health products to the producer
or consumer. Animal health products are shipped to locations closer to the final destination. The
segments trucking operations transport the products directly to the producer or consumer.
The Companys reportable segments are strategic business units that serve different types of
customers in the animal health industry. The separate financial information of each segment is
presented consistent with the way results are regularly evaluated by the chief operating decision
maker in deciding how to allocate resources and in assessing performance. See Note 14 of the
Companys 2009 Consolidated Financial Statements for additional quantitative segment information.
20
The following table summarizes the Companys operations by business segment:
Year Ended | ||||||||||||
July 31, 2009 | July 31, 2008 | July 31, 2007 | ||||||||||
(in thousands) | ||||||||||||
NET SALES AND OTHER REVENUE |
||||||||||||
Wholesale Distribution |
$ | 294,377 | $ | 338,376 | $ | 338,535 | ||||||
Logistics Services |
284 | 1,452 | 306 | |||||||||
Direct Customer Services |
55,566 | 63,532 | 57,085 | |||||||||
Eliminations |
(50,498 | ) | (63,522 | ) | (53,227 | ) | ||||||
Consolidated Total |
$ | 299,729 | $ | 339,838 | $ | 342,699 | ||||||
COST OF SALES |
||||||||||||
Wholesale Distribution |
268,275 | 301,511 | 303,949 | |||||||||
Logistics Services |
240 | 1,495 | 258 | |||||||||
Direct Customer Services |
50,733 | 55,780 | 50,001 | |||||||||
Eliminations |
(52,914 | ) | (63,190 | ) | (53,086 | ) | ||||||
Consolidated Total |
$ | 266,334 | $ | 295,596 | $ | 301,122 | ||||||
OPERATING, GENERAL AND
ADMINISTRATIVE EXPENSES |
||||||||||||
Wholesale Distribution |
32,459 | 33,045 | 29,106 | |||||||||
Logistics Services |
| | | |||||||||
Direct Customer Services |
7,345 | 7,389 | 6,971 | |||||||||
Eliminations |
| | | |||||||||
Consolidated Total |
$ | 39,804 | $ | 40,434 | $ | 36,077 | ||||||
BUSINESS SEGMENT ASSETS |
||||||||||||
Wholesale Distribution |
$ | 79,017 | $ | 80,392 | $ | 87,297 | ||||||
Logistics Services |
395 | 351 | 394 | |||||||||
Direct Customer Services |
11,823 | 14,906 | 13,075 | |||||||||
Eliminations |
(11,502 | ) | (14,455 | ) | (12,522 | ) | ||||||
Consolidated Total |
$ | 79,733 | $ | 81,194 | $ | 88,244 | ||||||
Wholesale Distribution
Net sales and other revenue for our wholesale distribution segment were $294.4 million in
2009, $338.4 million in 2008 and $338.5 million in 2007. The decrease in net sales and other
revenue in 2009 over 2008 resulted primarily because of a decrease in sales to existing customers
of $9.8 million, an increase in sales discounts to customers of $2.5 million, and an increase in
shareholder rebate of $0.7 million. Of this decrease $32.5 million was a result of the termination
of the SERVCO agreement. Partially offsetting this decrease was an increase in sales to new
customers of $1.5 million. The Companys shareholder rebate increased $0.7 million, compared to
the prior fiscal year-end, which is netted against sales and accounts receivable on the Companys
financial statements. The decrease in net sales and other revenue in 2008 over 2007 resulted
primarily because of a decrease in sales to existing customers of $14.8 million. Of this decrease
$3.2 million was a result of the termination of the logistical services agreement with SERVCO
effective June 30, 2008. Partially offsetting this decrease was an increase in sales to new
customers of $0.5 million, an increase in sales in consolidated affiliates of $10.1 million, an
increase in agency commission of $0.7 million, an increase in equity earnings of consolidated
affiliates of $0.2 million, and an increase in miscellaneous income of $0.2 million. The Companys
shareholder rebate decreased $3.0 million, compared to the prior fiscal year-end, which is netted
against sales and accounts receivable on the Companys financial statements.
Cost of sales were $268.3 million in 2009, $301.5 million in 2008 and $303.9 million in 2007.
The decrease in cost of sales in 2009 over 2008 resulted primarily from a decrease in cost of goods
sold of $36.9 million and a decrease in freight expense of $2.0 million. Partially offsetting this
decrease was a decrease in vendor sales and purchase incentives of $5.7 million. The cost of sales
includes the Companys inventory product cost and freight costs less vendor purchase and sales
incentives. The decrease in cost of sales in 2008 over 2007 resulted primarily from a decrease in
cost of goods sold of $3.4 million and an increase in vendor sales and purchase incentives of $2.3
million. Partially offsetting this decrease was an increase in freight expense of $3.3 million.
The cost of sales includes the Companys inventory product cost and freight costs less vendor
purchase and sales incentives.
21
Gross profit for our wholesale distribution segment was $26.1 million in 2009, $36.9 million
in 2008 and $34.6 million in 2007. The decrease in gross profit in 2009 over 2008 resulted
primarily from a decrease in vendor sales and purchase incentives of $5.7 million, Vets First
Choice expenses of $2.6 million and an increase in sales discounts to customers of $2.5 million.
The increase in gross profit in 2008 over 2007 resulted primarily from an increase in vendor sales
and purchase incentives of $2.3 million.
Operating, general and administrative expenses for our wholesale distribution segment were
$32.4 million in 2009, $33.0 million in 2008 and $29.1 million in 2007. The decrease in operating,
general and administrative expense in 2009 over 2008 resulted primarily from decreases in the
following: payroll, payroll taxes, and employee benefits of $0.6 million, profit sharing of $0.1
million, directors fees and expense of $0.1 million, convention and meetings of $0.1 million,
employee education of $0.4 million, communication expense of $0.2 million, operating supplies and
expense of $0.1 million, and postage of $0.5 million. Partially offsetting these decreases are
increases in the following: pharmacy fees of $0.2 million and computer supplies and support
expense of $0.9 million. The increase in computer support and expense resulted from the Companys
investment in technology in order to increase value to our customers and to the Company. The
increase in operating, general and administrative expense in 2008 over 2007 resulted primarily from
an increases in the following: payroll, payroll taxes, and employee benefits of $0.9 million,
professional services of $0.9 million, computer support and supplies expense of $0.9 million,
depreciation expense of $0.2 million, directors fees and expense of $0.1 million, employee
education of $0.1 million, employee reimbursed expenses of $0.1 million, communication expense of
$0.1 million, credit card fees of $0.1 million as well as a decrease in billable marketing income
of $0.6 million. The increases in operating, general and administrative expenses resulted from the
Companys investment in technology in order to increase value to our customers and to the Company.
Operating income (loss) for our wholesale distribution segment was $(6.3) million in 2009,
$3.8 million in 2008 and $5.5 million in 2007. The decrease in operating income from 2009 over
2008 resulted primarily from a decrease in gross profit margin of $10.8 million. Offsetting this
decrease was a decrease in operating, general and administrative expenses of $0.6 million. The
decrease in operating income from 2008 over 2007 resulted primarily from an increase in operating,
general and administrative expenses of $4.0 million. Offsetting this decrease was an increase in
gross profit margin of $2.3 million.
Assets decreased by $0.7 million to $79.7 million for fiscal year 2009 compared to $80.4
million for the previous year. This decrease was primarily due to a decrease in accounts receivable
of $2.1 million of which was a result of an increase in cash receipts from customers, a decrease in
income of consolidated affiliates of $2.3 million, a decrease in net property and equipment of $1.4
million, and a decrease in intercompany accounts of $0.6 million. Partially offsetting this
decrease was an increase in inventory of $2.5 million and an increase in prepaid expenses of $2.5
million.
Logistics Services
Net sales and other revenue for our logistic services segment were $0.3 million in 2009, $1.4
million in 2008 and $306 thousand in 2007. The decrease in net sales and other revenue in 2009 over
2008 resulted primarily due to a decrease in sales to other animal health wholesalers for
additional companion animal products purchased. The increase in net sales and other revenue in
2008 over 2007 resulted primarily due to an increase in sales to other animal health wholesalers
for additional companion animal products purchased.
Cost of sales for our logistics services segment were $0.2 million in 2009, $1.5 million in
2008 and $258 thousand in 2007. The decrease in cost of sales in 2009 over 2008 resulted primarily
from a decrease in cost of goods sold of $1.3 million. The increase in cost of sales in 2008 over
2007 resulted primarily from an increase in cost of goods sold of $1.2 million.
The gross profit (loss) for our logistic services segment was $44 thousand in 2009, $(43)
thousand in 2008 and $48 thousand in 2007. The increase in gross profit in 2009 over 2008 resulted
primarily due to the increase in gross profit margin. Operating, general and administrative
expenses for our logistic services segment are nominal. The decrease in gross profit (loss) in
2008 over 2007 resulted primarily due to the decrease in gross profit margin. During the period,
the Company sold a group of products below cost to reduce excess inventory levels of those items.
Operating, general and administrative expenses for our logistic services segment are nominal.
Operating income (loss) for our logistic services segment was $44 thousand in 2009, $(43)
thousand in 2008 and $48 thousand in 2007. The increase in operating income in 2009 over 2008
resulted primarily from an increase in gross profit margin of $87 thousand. The decrease in
operating income (loss) in 2008 over 2007 resulted primarily from a decrease in gross profit margin
of $91 thousand.
22
Assets increased by $44 thousand to $395 thousand for fiscal year 2009 compared to $351
thousand for the previous year. This increase was primarily due to an increase in accounts
receivable.
Direct Customer Services
Net sales and other revenue for our direct customer services segment were $55.6 million in
2009, $63.5 million in 2008 and $57.1 million in 2007. The decrease in net sales and other revenue
in 2009 over 2008 resulted primarily from a decrease in sales to existing customers of $24.7
million. Partially offsetting this decrease was an increase in sales to new customers of $16.8
million. The increase in net sales and other revenue in 2008 over 2007 resulted primarily from an
increase in sales to new customers of $4.5 million and an increase in sales to existing customers
of $1.9 million.
Cost of sales were $50.7 million in 2009, $55.8 million in 2008 and $50.0 million in 2007.
The decrease in cost of sales in 2009 over 2008 resulted primarily from a decrease in cost of goods
sold of $6.3 million. Partially offsetting this decrease was an increase in freight expense of
$0.5 million and a decrease in vendor purchases and sales incentives earned by the Company of $0.7
million. The cost of sales includes the Companys inventory product cost and freight less vendor
purchases and sales incentives. The increase in cost of sales in 2008 over 2007 resulted primarily
from an increase in cost of goods sold of $6.8 million. Partially offsetting this increase was a
decrease in freight expense of $0.5 million, and an increase in vendor purchases and sales
incentives earned by the Company of $0.5 million. The cost of sales includes the Companys
inventory product cost and freight less vendor purchases and sales incentives.
Gross profit for our direct customer services segment was $4.8 million in 2009, $7.8 million
in 2008 and $7.1 million in 2007. The decrease in gross profit in 2009 over 2008 resulted primarily
from a decrease in vendor sales and purchase incentives of $0.7 million and an increase in freight
expense of $0.5 million. The increase in gross profit in 2008 over 2007 resulted primarily from
an increase in vendor sales and purchase incentives of $0.5 million and a decrease in freight
expense of $0.5 million. Partially offsetting this increase was an increase in sales incentive
discounts of $0.5 million.
Operating, general and administrative expenses for our direct customer services segment were
$7.3 million in 2009, $7.4 million in 2008 and $7.0 million in 2007. The decrease in operating,
general and administrative expenses in 2009 over 2008 resulted primarily from a decrease in
payroll, payroll taxes and employee benefits of $0.2 million, a decrease in vet of record
commission of $0.2 million, and a decrease in royalty commission of $0.1 million. Partially
offsetting these decreases is an increase in bad debt expense of $0.4 million. The increase in
operating, general and administrative expenses in 2008 over 2007 resulted primarily from an
increase in mileage reimbursement expense of $0.1 million and a decrease in billable marketing
income of $0.3 million.
Operating income (loss) for our direct customer services segment was $(2.5) million in 2009,
$0.4 million in 2008 and $0.1 million in 2007. The decrease in operating income (loss) in 2009 over
2008 resulted primarily from a decrease in gross profit margin of $3.0 million. Offsetting this
decrease was a decrease in operating, general and administrative expenses of $0.1 million. The
increase in operating income in 2008 over 2007 resulted primarily from an increase in gross profit
margin of $0.7 million. Offsetting this increase was an increase in operating, general and
administrative expenses of $0.4 million.
Assets decreased by $3.1 million to $11.8 million for fiscal year 2009 compared to $14.9
million for the previous year. This decrease was primarily due to a decrease in accounts receivable
of $1.7 million, a decrease in inventory of $1.3 million, and a decrease in property plant and
equipment of $0.1 million.
Seasonality in Operating Results
The Companys quarterly sales and operating results have varied in the past and will likely
continue to do so in the future. Historically, the Companys livestock sales are seasonable with
peak sales in the spring and fall. The cyclical nature is directly tied to certain medical
procedures performed by veterinarians on livestock during these seasons.
In the last few years, the Company has been selling more companion animal related products.
These products have a different seasonal nature which minimally overlaps the livestock business
cycles. The net result is a reduction of the cyclical seasonal nature of the business. Minimizing
the cyclical nature of the Companys business has allowed for more efficient utilization of all
resources.
23
Liquidity and Capital Resources
The Company expends capital primarily to fund day-to-day operations and expand those
operations to accommodate sales growth. It is necessary for the Company to expend funds to maintain
significant inventory levels in order to fulfill its commitment to its customers. Historically, the
Company has financed its cash requirements primarily from short term bank borrowings and cash from
operations. At July 31, 2009, there were no additional material commitments for capital
expenditures other than as noted below.
The Company also expended significant funds in the lease and purchase of its facilities. The
Company leases a total of 87,500 square feet from Kinsley Equities II Limited Partnership for
warehouse space in York, Pennsylvania. The payment for this lease is $0.03 million per month.
For additional information, see the section Properties.
In November 2006, the Company and its subsidiaries executed a Loan Agreement and related loan
documents (collectively Loan Documents) with First National Bank of Omaha (FNB). The obligations
of the Company and its subsidiaries under the Loan Documents are joint and several. At July 31,
2009, pursuant to the terms of the Loan Documents, FNB could loan to the Company and its
subsidiaries up to $44.7 million, which includes a $40 million revolving loan facility and a $4.7
million term loan facility. On August 21, 2009, the principal amount of the revolving credit
facility was decreased from $40 million to $37.5 million. The Company shall pay FNB a non-usage
fee at the rate of .10% per annum of the unused portion of the $37.5 million revolving loan. The
non-usage fee shall be payable in arrears on each January 1, April 1, July 1, and October 1 and on
the termination date.
The Term Note is amortized over a ten year period with a final maturity date of December 1,
2016. The interest rate is fixed at 7.35% per annum for the term of the note. Upon an event of
default, the Term Note shall bear interest at the LIBOR Rate as determined by FNB plus 7.50% per
annum. This Term Note may not be prepaid without obtaining the consent of FNB and payment of the
prepayment fee as calculated therein. Installments of principal and interest in the amount of
$0.05 million are due on the first day of each month until and including November 1, 2016. On
December 1, 2016, all unpaid principal and interest thereon shall be due and payable. As of July
31, 2009, the Company had $3.7 million outstanding on the Term Note.
FNB shall provide advances to the Company from the Revolving Note in the maximum aggregate
amount of $37.5 million, which advances will be used as needed by the Company for working capital,
through the termination date of December 1, 2009. Interest shall be paid at a variable rate, reset
monthly equal to the LIBOR as determined by FNB plus (i) 1.25% per annum when the cash flow
leverage ratio is less than or equal to 3.00 to 1.00 or (ii) 1.50% per annum when the cash flow
leverage ratio is more than 3.00 to 1.00. The Loan Agreement imposes certain financial covenants,
and the Company shall not, without consent of FNB, permit its minimum tangible net worth to be less
than $17 million or its cash flow leverage ratio to be equal to or greater than 3.50 to 1.00. The
loans may be accelerated upon default. Event of default provisions include, among other things,
the Companys failure to (i) pay amounts when due and to (ii) perform any material condition or
comply with any material promise or covenant of the Loan Documents. The Revolving Note and Term
Note are secured by substantially all of the assets of the Company and its subsidiaries, including
the Companys headquarters in Omaha. We also are restricted from paying dividends by these credit
facilities. For the fiscal year ended
July 31, 2009 the Company was in violation of certain of these
covenants for which a waiver of non-compliance was received from the
lender.
On November 19, 2008, the Company and FNB amended the Loan Agreement to allow the Company to
enter into interest rate swap transactions from time-to-time. Pursuant to that amendment, interest
shall be paid on the revolving note at a variable rate, reset monthly, equal to LIBOR Rate as
determined by Lender plus (i) 1.25% per annum when the cash flow leverage ratio is less than or
equal to 3.00 or 1.00 (ii) 1.50% per annum when the cash flow leverage ratio is more than 3.00 to
1.00. As a result of the interest rate swap, the Company is paying effective interest rate of
4.59% for borrowings up to $10.0 million for the period ending July 31, 2009. Upon the event of
default, the Revolving Note shall bear interest at the LIBOR as determined by FNB plus 7.50% per
annum. As of July 31, 2009, the variable interest rate at which the Revolving Note accrued
interest was 1.81%, and the Company had approximately $20.3 million outstanding thereunder.
On December 27, 2006, the Company and Jelecos entered into a statement of work agreement for
consulting services. Jelecos provides the Company with strategic technology consulting services
including, but not limited to, project analysis, staffing analysis, product and process evaluation,
capacity analysis and overall infrastructure analysis as related to current and future business
objectives. The estimated monthly recurring fee is approximately $0.1 million.
24
On March 21, 2008, the Company and Revenue Analytics entered into a statement of work
agreement for consulting services through July 31, 2008. The Company partnered with Revenue
Analytics to develop targeted pricing strategies, processes and monitoring capabilities at the
customer segment level. On May 27, 2009, the Company and Revenue Analytics entered into a third
statement of work agreement for consulting services through May 31, 2010. The fees paid through
July 31, 2009 were $719,520 for 12 months.
Under its Bylaws, the Company may, in its discretion, decide to repurchase shares of common
stock upon request for redemption by a shareholder.
Operating Activities. For the fiscal year ending July 31, 2009, net cash used in operating
activities of $6.5 million was primarily as a result of $1.1 million net increase in inventory, a
$2.2 million net increase in other current assets, and a $3.6 million net decrease in accounts
payable. For the fiscal year ending July 31, 2008, net cash provided by operating activities of
$1.2 million was primarily as a result of $0.2 million net decrease in receivables. For the fiscal
year ending July 31, 2007, net cash consumed by operating activities of $4.8 million was primarily
attributable to an increase in accounts receivable of $7.1 million and an increase in inventory of
$7.4 million. These were partially offset by an increase of $3.3 million in accounts payable and
an increase in other current liabilities of $1.5 million.
Investing Activities. Net cash consumed by investing activities of $0.9 million in fiscal year
ending July 31, 2009 was primarily attributable to an increase in investments in equipment,
including the purchase of office, warehouse and computer equipment of $0.5 million and a $0.4
million net increase in cash value of life insurance. Net cash consumed by investing activities of
$0.8 million in fiscal year ending July 31, 2008 was primarily attributable to an increase in
investments in equipment, including the purchase of office, warehouse and computer equipment of
$1.7 million. This was partially offset by the proceeds from the sale of unconsolidated affiliate
for $1.4 million. Net cash consumed by investing activities of $2.0 million in fiscal year ending
July 31, 2007 was primarily attributable to investments in equipment, including the purchase of
office, warehouse and computer equipment.
Financing Activities. In the fiscal year ending July 31, 2009, net cash provided by financing
activities of $6.8 million was primarily attributable to $7.4 million in net loan proceeds. This
was partially offset by the payments of long-term debt and capital lease obligation of $0.4
million. In the fiscal year ending July 31, 2008, net cash provided by financing activities of $0.5
million was primarily attributable to $0.9 million in net loan proceeds. This was partially offset
by the payments of long-term debt and capital lease obligation of $0.4 million. In the fiscal year
ending July 31, 2007, net cash provided by financing activities of $5.3 million was primarily
attributable to $5.3 million in net loan proceeds.
Inflation
Most of our operating expenses are inflation-sensitive with inflation generally producing
increased costs of operations. During the past three years, the most significant effects of
inflation have been on employee wages and costs of products.
Off-Balance Sheet Arrangements
At July 31, 2009, the Company did not have any off-balance sheet arrangements.
Critical Accounting Policies
The Securities and Exchange Commission (SEC) issued disclosure guidance for critical
accounting policies. The SEC defines critical accounting policies as those that require
application of managements most difficult, subjective or complex judgments, often as a result of
the need to make estimates about the effect of matters that are inherently uncertain and may change
in subsequent periods.
The Companys significant accounting policies are described in Note 1 to the Consolidated
Financial Statements. Not all of these significant accounting policies require management to make
difficult, subjective or complex judgments or estimates. However, management of the Company is
required to make certain estimates and assumptions during the preparation of consolidated financial
statements in accordance with accounting principles generally accepted in the United States of
America. These estimates and assumptions impact the reported amount of assets and liabilities and
disclosures of contingent assets and liabilities as of the date of the consolidated financial
25
statements. Estimates and assumptions are reviewed periodically and the effects of revisions
are reflected in the period they are determined to be necessary. Actual results could differ from
those estimates. Following are some of the Companys critical accounting policies impacted by
judgments, assumptions and estimates.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual amounts could differ from those estimates.
Revenue Recognition
The Company derives its revenues primarily from the sale of products and agency agreements.
Revenues are recognized as product is received by the customer and related services are performed
in accordance with all applicable revenue recognition criteria. For these transactions, the
Company applies the provisions of the SEC Staff Accounting Bulletin No. 104, Revenue Recognition.
The revenue from the buy/sell transactions are recorded at gross. Agency sales are transactions
presented on a net basis. The Company recognizes revenue when there is pervasive evidence of an
arrangement, title and risk of loss have passed, delivery has occurred or the contractual
obligations are met, the sales price is fixed or determinable and collection of the related
receivable is reasonably assured.
Inventories
Inventories consist substantially of finished goods held for resale and are valued at the
lower of cost or market, not in excess of net realizable value. Cost is determined primarily by the
weighted average cost method.
Major Customers, Major Suppliers and Credit Concentrations
Other financial assets and liabilities, which potentially subject the Company to
concentrations of credit risk, are trade accounts receivable and trade payables. Two vendors
comprised 52.2% of all purchases for the year ended July 31, 2009. Two vendors comprised 48.3% of
all purchases for the year ended July 31, 2008.
Income Taxes
The Company provides for income taxes using the asset and liability method under which
deferred income taxes are recognized for the estimated future tax effects attributable to temporary
differences and carry-forwards that result from events that have been recognized either in the
financial statements or the income tax returns, but not both. The measurement of current and
deferred income tax liabilities and assets is based on provisions of enacted laws. Valuation
allowances are recognized if, based on the weight of available evidence, it is more likely than not
that some portion of the deferred tax assets will not be realized. For further discussion, see Note
6 to the Consolidated Financial Statements.
Other Intangible Assets
Other identifiable intangible assets consist of the Company trademark and loan origination
fees. Trademarks have an indefinite life and therefore are not amortized. Loan origination fees
constitute the Companys identifiable intangible asset subject to amortization. Amortization of the
loan origination fees is computed on a straight-line basis over the term of the related note.
Amortization expense for the years ended July 31, 2009, 2008, and 2007 is included in interest
expense on the Consolidated Statements of Income and Comprehensive Income.
Pension
Accounting
On January 1, 2003, the Company adopted a Supplemental Executive Retirement Plan (SERP). The
SERP is a nonqualified defined benefit plan pursuant to which the Company will pay supplemental
pension benefits to certain key employees upon retirement based upon the employees years of
service and compensation. As of July 31, 2007, the Company adopted the provisions of SFAS No. 158,
Employers Accounting for Defined Benefit Pension and Other Postretirement Plans and in accordance
therewith reflected the underfunded status of the plan in its balance sheet at such date.
Prospectively, the Company adjusted the liability to reflect the current funded status of the plan.
Any gains or losses that arose during the period but are not recognized as components of net
periodic benefit cost was recognized as a component of other comprehensive income. The adoption of
SFAS No. 158 resulted in the recognition of $516 of unrecognized actuarial losses which arose
during the period ending July 31,
26
2009 and a corresponding increase in the defined benefit pension plan liability at July 31,
2009. Such unrecognized losses, net of deferred taxes of $207 were debited to other comprehensive
income. The adoption of SFAS No. 158 resulted in the recognition of $642 of unrecognized actuarial
losses which arose during the period ending July 31, 2008 and a corresponding increase in the
defined benefit pension plan liability at July 31, 2008. Such unrecognized losses, net of deferred
taxes of $257 were debited to other comprehensive income. The adoption of SFAS No. 158 resulted in
the recognition of $646 of unrecognized actuarial losses which arose during the period ended July
31, 2007 and a corresponding increase in the defined benefit pension plan liability at July 31,
2007. Such unrecognized losses, net of deferred taxes of $258 were debited to other comprehensive
income. The adoption of SFAS No. 158 had no effect on the Companys consolidated statement of
income for the period ended July 31, 2007.
For the year ended July 31, 2009 and 2008, benefits accrued and expensed were $324 and $344,
respectively. The vested benefit obligation and accumulated benefit obligation were $2,836 and
$2,955, respectively, at July 31, 2009 and $2,474 and $2,729, respectively, at July 31, 2008. The
plan is an unfunded supplemental retirement plan and is not subject to the minimum funding
requirements of the Employee Retirement Income Security Act (ERISA). While the SERP is an unfunded
plan, the Company is informally funding the plan through life insurance contracts on the
participants. The life insurance contracts had cash surrender values of $2,709 and $2,238 at July
31, 2009 and 2008, respectively. For further discussion, see Note 9 to the Consolidated Financial
Statements.
New Accounting Pronouncements
The Company adopted FASB SFAS No. 157, Fair Value Measurements, as of August 1, 2008. This
statement defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles, and expands disclosures about fair value measurements. This
statement emphasizes that fair value is a market-based measurement, not an entity specific
measurement. Therefore, a fair value measurement should be determined based on the assumptions
that market participants would use in pricing the asset or liability. As a basis for considering
market participant assumptions in fair value measurements, this statement establishes a fair value
hierarchy that distinguishes between the market participant assumptions developed based on market
data obtained from sources independent of the reporting entity and the reporting entitys own
assumptions about market participant assumptions developed based on the best information available
in the circumstances. This statement is effective for financial statements issued for fiscal years
beginning after November 15, 2007. The adoption of this statement did not have a material effect
on the Companys financial position, cash flows or results of operations.
In March 2008, FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities an amendment of FASB Statement No. 133. This statement is intended to enhance the
current disclosure framework in SFAS No. 133. The statement requires that objectives for using
derivative instruments be disclosed in terms of underlying risk and accounting designation. This
disclosure better conveys the purpose of derivative use in terms of the risks that the entity is
intending to manage. This statement is effective for financial statements issued for fiscal years
and interim periods beginning after November 15, 2008. This statement does not require comparative
disclosures for earlier periods at initial adoption. The adoption of this statement as of February
1, 2009 did not have a material effect on the Companys financial position, cash flows
or results of operations.
In May 2009, FASB issued SFAS No. 165, Subsequent Events. This statement is intended to
establish general standards of accounting for and disclosure of events that occur after the balance
sheet date but before financial statements are issued or are available to be issued. This
statement should be applied to the accounting for and disclosure of subsequent events. This
statement does not apply to subsequent events or transactions that are within the scope of other
applicable generally accepted accounting principles (GAAP) that provide different guidance on the
accounting treatment for subsequent events or transactions. This statement would apply to both
interim financial statements and annual financial statements. The adoption of this statement as of
June 15, 2009 did not have a material effect on the Companys financial position, cash
flows or results of operations.
In June 2009, FASB issued SFAS No. 168, The FASB Accounting Standards Codification and the
Hierarchy of Generally Accepted Accounting Principles a replacement of FASB Statement No. 162.
This statement will become the source of authoritative U.S. generally accepted accounting
principles (GAAP) recognized by the FASB to be applied by nongovernmental entities. Rules and
interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal
securities laws are also sources of authoritative GAAP for SEC registrants. On the effective date
of this statement, the codification will supersede all then-existing non-SEC accounting and
reporting standards. The adoption of this statement as of September 15, 2009 is not expected to
have a material effect on the Companys financial position, cash flows or results of operations.
27
ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
The Company is exposed to market risks primarily from changes in interest rates. The Company
does not engage in financial transactions for trading or speculative purposes.
As disclosed under Liquidity and Capital Resources, the Company and its subsidiaries have a
$40 million revolving loan facility and a $4.7 million term loan facility with FNB. The interest
rate of the Term Note is fixed at 7.35% per annum except in the event of default. As of July 31,
2009, the Company had $3.4 million outstanding on the Term Note. The interest rate of the
Revolving Note fluctuates and is paid at a variable rate, reset monthly, equal to the LIBOR Rate as
determined by FNB plus (i) 1.25% per annum when the cash flow leverage ratio is less than or equal
to 3.00 to 1.00 or (ii) 1.50% per annum when the cash flow leverage ratio is more than 3.00 to
1.00, except in the event of default. As of July 31, 2009, the variable interest rate at which the
Revolving Note accrued interest was 1.81% and the Company had approximately $20.3 million
outstanding thereunder.
As a strategy to maintain acceptable levels of exposure to the risk of changes in future cash
flows to interest rate fluctuations, the Company entered into an interest rate swap agreement for a
portion of its floating rate debt. The agreement provides for the Company to receive interest from
the counterparty at LIBOR and to pay interest to the counterparty at fixed rate of 3.09% on
notional amounts of $10 million at July 31, 2009. As a result of the interest rate swap, the
Company is paying effective interest rate of 4.59% for borrowings up to $10 million for the period
ending July 31, 2009. Under the agreement, the Company pays or receives the net interest monthly,
with the monthly settlements included in interest expense.
The interest payable on the Companys revolving line of credit is based on variable interest
rates and is therefore affected by changes in the market interest rates. If interest rates on
variable debt rose .20 percentage points (a 10% change from the interest rate as of July 31, 2009),
assuming no change in the Companys outstanding balance under the line of credit (approximately
$20.3 million as of July 31, 2009), the Companys annualized income before taxes and cash flows
from operating activities would decline by approximately $36 thousand.
28
ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
Report of Independent Registered Public Accounting Firm |
F-1 | |||
Report of Independent Registered Public Accounting Firm |
F-2 | |||
Consolidated Balance Sheets as of July 31, 2009 and
July 31, 2008 |
F-3 | |||
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Years Ended July 31, 2009, 2008 and 2007 |
F-4 | |||
Consolidated Statements of Stockholders Equity Years Ended
July 31, 2009, 2008 and 2007 |
F-5 | |||
Consolidated Statements of Cash Flows Years Ended July 31, 2009, 2008
and 2007 |
F-6 | |||
Notes to Consolidated Financial Statements |
F-7 |
ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE |
On May 18, 2007, the Companys Audit Committee recommended to the Board of Directors the
dismissal of Quick and McFarlin upon its completion of the audit and the filing of the Form 10-K
for the fiscal year ending July 31, 2007 and the retention of BKD LLP (BKD) as the Companys
independent accountant for the fiscal year ending July 31, 2008. The Board of Directors approved
the Audit Committees recommendations, subject to acceptance by BKD of its engagement.
For the fiscal years ended July 31, 2006 and 2007, Quick & McFarlins reports on such
financial statements did not contain any adverse or a disclaimer of opinion and were not qualified
or modified as to uncertainty, audit scope, or accounting policies. There were no disagreements
with Quick & McFarlin on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure which disagreements, if not resolved to the satisfaction
of Quick & McFarlin, would have caused Quick & McFarlin to make reference to the subject matter of
the disagreement in connection with its report, and there were no reportable events as described
Item 304(a)(1)(v) of Regulation S-K.
The Company previously disclosed its change in accountants on a Current Report on Form 8-K
dated May 18, 2007, and filed on May 24, 2007 with the SEC and an amendment to the Form 8-K filed
on July 31, 2007.
ITEM 9A. CONTROLS AND PROCEDURES
The following report shall not be deemed to be filed for purposes of Section 18 of the Exchange Act
or otherwise subject to the liabilities of that section, unless the registrant specifically states
that the report is to be considered filed under the Exchange Act or incorporates it by reference
into a filing under the Securities Act or the Exchange Act:
Managements Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over our
financial reporting. Internal control over financial reporting is a process designed to provide
reasonable assurance to our management and Board of Directors regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance
with U.S. generally accepted accounting principles. Our internal control over financial reporting
includes those policies and procedures that (i) pertain to the maintenance of records that in
reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance
that transactions are recorded as necessary for preparation of our financial statements; (iii)
provide reasonable assurance that receipts and expenditures of Company assets are made in
accordance with management authorization; and (iv) provide reasonable assurance that unauthorized
acquisition, use or disposition of Company assets that could have a material effect on our
financial statements would be prevented or detected on a timely basis.
Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because changes in conditions may occur
or the degree of compliance with the policies or procedures may deteriorate.
A material weakness is a deficiency, or a combination of control deficiencies, in internal
control over financial reporting, such that there is a reasonable possibility that a material
misstatement or annual or interim financial statements would not be prevented or detected on a
timely basis.
Management assessed the effectiveness of our internal control over financial reporting as of
July 31, 2009. This assessment is based on the criteria for effective internal control described
in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of
the Treadway Commission. Based on its assessment, management concluded that our internal control
over financial reporting was not effective as of July 31, 2009. The Company identified a material
weakness relating to controls over physical inventory after the Company failed to locate a pallet
of inventory valued at approximately $232,000.
This annual report does not include an attestation report of our registered public accounting
firm regarding internal control over financial reporting. Managements Report was not subject to
attestation by our registered public accounting firm pursuant to temporary rules of the Securities
and Exchange Commission that permit us to provide only Managements Report in this annual report.
Evaluation of Disclosure Controls and Procedures
An evaluation of the effectiveness of the design and operation of the Companys disclosure
controls and procedures (as defined in Section 13a-15(e) of the Securities Exchange Act of 1934
(the Exchange Act)) was carried out under the supervision and with the participation of our Chief
Executive Officer and Chief Financial Officer as of the end of the period covered by this annual
report. Based on that evaluation and the material weakness described above, our Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not
effective in ensuring that the information required to be disclosed by us in the reports that we
file or submit under the Exchange Act is (i) accumulated and communicated to Company management
(including the Chief Executive Officer and Chief Financial Officer) to allow timely decisions
regarding disclosures, and (ii) recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commissions rules and forms. Under the direction
of the Chief Executive Officer and Chief Financial Officer, the Company evaluated its disclosure
controls and procedures, identified a material weakness relating to the controls over physical
inventory, and, accordingly, does not believe that its disclosure controls and procedures were
effective at July 31, 2009.
29
The Company intends to continue to monitor its disclosure controls and procedures, and if
further improvements or enhancements are identified, the Company will take steps to implement such
improvements or enhancements. It should be noted that the design of any system of controls is
based upon certain assumptions about the likelihood of future events, and there can be no assurance
that such design will succeed in achieving its stated objective under all potential future
conditions, regardless of how remote. However, the Companys Chief Executive Officer and the
Companys Chief Financial Officer believe the Companys disclosure controls and procedures provide
reasonable assurance that the disclosure controls and procedures are effective.
Changes in Internal Controls
Except for the material weakness described above, during the quarter ended July 31, 2009,
there were no significant changes in our internal control over financial reporting that have
materially affected or that are reasonably likely to affect the Companys internal control over
financial reporting.
Subsequent to July 31, 2009, the Company took the following actions to remediate the material
weakness relating to the controls over physical inventory:
1. Enhanced physical inventory count procedures to ensure more accurate counts and that
controls are operating effectively;
2. Implemented an additional cycle account for high dollar products, including daily counts
of products in the event of inventory discrepancies; and
3. Educated management and employees on multi-product packaging.
Management continues to engage in substantial efforts to remediate the material weakness noted
above. These remedial actions are intended to address the identified material weakness and enhance
the Companys overall internal control over financial reporting. The Company anticipates full
remediation of the material weakness relating to the controls over physical inventory prior to the
end of the second fiscal quarter.
Limitations on the Effectiveness of Controls
The Company has confidence in its internal controls and procedures. Nevertheless, the
Companys management (including the Chief Executive Officer and Chief Financial Officer) believes
that a control system, no matter how well designed and operated can provide only reasonable
assurance and cannot provide absolute assurance that the objectives of the internal control system
are met, and no evaluation of internal controls can provide absolute assurance that all control
issues and instances of fraud, if any, within a company have been detected. Further, the design of
an internal control system must reflect the fact that there are resource constraints, and the
benefits of controls must be considered relative to their costs. Because of the inherent limitation
in all internal control systems, no evaluation of controls can provide absolute assurance that all
control issuers and instances of fraud, if any, within the Company have been detected.
30
assurance that the objectives of the internal control system are met, and no evaluation of
internal controls can provide absolute assurance that all control issues and instances of fraud, if
any, within a company have been detected. Further, the design of an internal control system must
reflect the fact that there are resource constraints, and the benefits of controls must be
considered relative to their costs. Because of the inherent limitation in all internal control
systems, no evaluation of controls can provide absolute assurance that all control issuers and
instances of fraud, if any, within the Company have been detected.
ITEM 9B. | OTHER INFORMATION |
The Registrant is not aware of any information required to be disclosed in a report on Form
8-K during the fourth quarter ended July 31, 2009.
PART III
ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
Incorporated by reference in this Annual Report is the information required by this Item 10
contained in the sections entitled Proposal 1: Election of Directors, Information About
Directors and Executive Officers and Section 16(a) Beneficial Ownership Reporting Compliance of
the Companys definitive proxy statement, to be filed pursuant to Regulation 14A with the SEC
within 120 days after July 31, 2009.
ITEM 11. | EXECUTIVE COMPENSATION |
Incorporated by reference in this Annual Report is the information required by this Item 11
contained in the section entitled Management Executive Compensation of the Companys definitive
proxy statement, to be filed pursuant to Regulation 14A with the SEC within 120 days after July 31,
2009.
ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS |
Incorporated by reference in this Annual Report is the information required by this Item 12
contained in the section entitled Security Ownership of Certain Beneficial Owners and Management
of the Companys definitive proxy statement, to be filed pursuant to Regulation 14A with the SEC
within 120 days after July 31, 2009.
ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE |
Incorporated by reference in this Annual Report is the information required by this Item 13
contained in the section entitled the Certain Relationships and Related Transactions of the
Companys definitive proxy statement, to be filed pursuant to Regulation 14A with the SEC within
120 days after July 31, 2009.
ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES |
Incorporated by reference in this Annual Report is the information required by this Item 14
contained in the section entitled the Relationship with Independent Public Accountants Principal
Accounting Fees and Services of the Companys definitive proxy statement, to be filed pursuant to
Regulation 14A with the SEC within 120 days after July 31, 2009.
31
PART IV
ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
(a) The following documents are filed as part of this report:
1) | Consolidated Financial Statements: See Index to Consolidated Financial Statements at item 8 on page 29 of this report. | ||
2) | Financial Statement Schedule: Schedule II Consolidated Valuation and Qualifying Accounts. | ||
3) | Exhibits are incorporated herein by reference or are filed with this report as set forth in the Index to Exhibits on pages II-1 through II-2 hereof. |
PROFESSIONAL VETERINARY PRODUCTS, LTD.
SCHEDULE II-CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS
(Amounts in thousands)
SCHEDULE II-CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS
(Amounts in thousands)
Balance at | Charged to | Balance at | ||||||||||||||
beginning of | costs and | end of | ||||||||||||||
period | expenses | Deductions | period | |||||||||||||
Allowance for doubtful accounts (in thousands) |
||||||||||||||||
Year ended July 31, 2009 |
$ | 501 | $ | 521 | $ | 717 | $ | 305 | ||||||||
Year ended July 31, 2008 |
515 | 190 | 204 | 501 | ||||||||||||
Year ended July 31, 2007 |
569 | (13 | ) | 41 | 515 | |||||||||||
Year ended July 31, 2006 |
970 | 76 | 477 | 569 | ||||||||||||
Year ended July 31, 2005 |
821 | 656 | 507 | 970 | ||||||||||||
Allowance for obsolete inventory (in thousands) |
||||||||||||||||
Year ended July 31, 2009 |
$ | 182 | $ | 291 | $ | 346 | $ | 127 | ||||||||
Year ended July 31, 2008 |
127 | 55 | | 182 | ||||||||||||
Year ended July 31, 2007 |
63 | 64 | | 127 | ||||||||||||
Year ended July 31, 2006 |
152 | | 89 | 63 | ||||||||||||
Year ended July 31, 2005 |
129 | 23 | | 152 |
32
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Audit Committee, Board of Directors and Stockholders
Professional Veterinary Products, Ltd.
Omaha, Nebraska
We have audited the accompanying consolidated balance sheets of Professional Veterinary
Products, Ltd. (the Company) as of July 31, 2009 and 2008, and the related consolidated
statements of income (loss) and comprehensive income (loss), stockholders equity and cash flows
for the years then ended. The Companys management is responsible for these financial statements.
Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audit included consideration of internal control
over financial reporting as a basis for designing auditing procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
Companys internal control over financial reporting. Accordingly, we express no such opinion. Our
audits also included examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and significant estimates made
by management, and evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all
material respects, the financial position of Professional Veterinary Products, Ltd. as of July 31,
2009 and 2008, and the results of its operations and its cash flows
for the years then ended, in conformity with accounting principles generally accepted in the United States of
America.
As discussed in Note 12, in 2009 the Company changed its method of accounting for fair value
measurements in accordance with statement of Financial Accounting Standards No. 157.
BKD LLP
Omaha, Nebraska
October 29, 2009
Omaha, Nebraska
October 29, 2009
F-1
Report of Independent Registered Public Accounting Firm
To the Audit Committee
Professional Veterinary Products, Ltd.
Omaha, Nebraska
Professional Veterinary Products, Ltd.
Omaha, Nebraska
We have audited the accompanying consolidated statements of income and comprehensive income,
stockholders equity, and cash flows of Professional Veterinary Products, Ltd. and subsidiaries
(the Company) for the year ended July 31, 2007. These financial statements are the responsibility
of the Companys management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material
respects, the consolidated results of operations and cash flows of Professional Veterinary
Products, Ltd. and subsidiaries for the year ended July 31, 2007, in conformity with accounting
principles generally accepted in the United States of America.
Quick & McFarlin, P.C.
Omaha, Nebraska
October 17, 2007
Omaha, Nebraska
October 17, 2007
F-2
PROFESSIONAL VETERINARY PRODUCTS, LTD.
CONSOLIDATED BALANCE SHEETS
July 31, 2009 and 2008
(in thousands, except share data)
July 31, | July 31, | |||||||
2009 | 2008 | |||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash |
$ | 1,408 | $ | 1,985 | ||||
Accounts receivable, net of allowance: |
||||||||
2009 - $305, 2008 - $501 |
24,227 | 27,782 | ||||||
Accounts receivable, related parties |
348 | 663 | ||||||
Inventory |
37,107 | 35,906 | ||||||
Deferred tax asset |
952 | 599 | ||||||
Other current assets |
3,518 | 1,271 | ||||||
Total current assets |
67,560 | 68,206 | ||||||
NET PROPERTY AND EQUIPMENT |
8,718 | 10,200 | ||||||
OTHER ASSETS |
||||||||
Intangible
assets, less accumulated amortization, $10 and $7, respectively |
30 | 33 | ||||||
Investment in unconsolidated affiliates |
144 | 144 | ||||||
Cash value of life insurance |
2,826 | 2,351 | ||||||
Deferred tax asset |
446 | 257 | ||||||
Other assets |
9 | 3 | ||||||
Total other assets |
3,455 | 2,788 | ||||||
TOTAL ASSETS |
$ | 79,733 | $ | 81,194 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Note payable, bank |
$ | 20,287 | $ | 12,860 | ||||
Current portion of long-term debt |
400 | 371 | ||||||
Current portion of accrued retirement benefits |
243 | 115 | ||||||
Accounts payable |
29,043 | 32,801 | ||||||
Accounts payable, related parties |
845 | 738 | ||||||
Interest rate swap |
111 | | ||||||
Other current liabilities |
3,656 | 4,093 | ||||||
Total current liabilities |
54,585 | 50,978 | ||||||
LONG-TERM LIABILITIES |
||||||||
Long-term debt |
3,370 | 3,767 | ||||||
Accrued retirement benefits |
2,811 | 2,853 | ||||||
Total long-term liabilities |
6,181 | 6,620 | ||||||
TOTAL LIABILITIES |
60,766 | 57,598 | ||||||
STOCKHOLDERS EQUITY |
||||||||
Common stock, $1 par value; authorized 30,000 shares; issued
and outstanding 2009 - 1,948 shares, 2008 - 2,037 shares |
2 | 2 | ||||||
Additional paid-in capital |
5,779 | 6,044 | ||||||
Retained earnings |
13,562 | 17,935 | ||||||
Accumulated other comprehensive loss |
(376 | ) | (385 | ) | ||||
Total stockholders equity |
18,967 | 23,596 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY |
$ | 79,733 | $ | 81,194 | ||||
See Notes to Consolidated Financial Statements.
F-3
PROFESSIONAL VETERINARY PRODUCTS, LTD.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)
Years Ended July 31, 2009, 2008 and 2007
(in thousands)
July 31, | July 31, | July 31, | ||||||||||
2009 | 2008 | 2007 | ||||||||||
NET SALES AND OTHER REVENUE |
$ | 299,729 | $ | 339,838 | $ | 342,699 | ||||||
COST OF SALES |
266,334 | 295,596 | 301,122 | |||||||||
Gross profit |
33,395 | 44,242 | 41,577 | |||||||||
OPERATING, GENERAL AND ADMINISTRATIVE
EXPENSES |
39,804 | 40,434 | 36,077 | |||||||||
OPERATING INCOME (LOSS) |
(6,409 | ) | 3,808 | 5,500 | ||||||||
OTHER INCOME (EXPENSE) |
||||||||||||
Interest income |
360 | 318 | 260 | |||||||||
Interest expense |
(1,095 | ) | (1,379 | ) | (1,936 | ) | ||||||
Equity in earnings of unconsolidated affiliate |
| 53 | 116 | |||||||||
Loss on the sale of unconsolidated affiliate |
| (571 | ) | | ||||||||
Other |
| (1 | ) | (81 | ) | |||||||
Other expense net |
(735 | ) | (1,578 | ) | (1,641 | ) | ||||||
INCOME (LOSS) BEFORE INCOME TAXES |
(7,144 | ) | 2,230 | 3,859 | ||||||||
PROVISION FOR INCOME TAXES |
(2,771 | ) | 802 | 1,475 | ||||||||
NET INCOME (LOSS) |
(4,373 | ) | 1,428 | 2,384 | ||||||||
EARNINGS (LOSS) PER COMMON SHARE |
$ | (2,201.91 | ) | $ | 697.92 | $ | 1,169.27 | |||||
Weighted average common shares outstanding |
1,986 | 2,046 | 2,039 | |||||||||
OTHER COMPREHENSIVE INCOME (LOSS) |
||||||||||||
Net income (loss) |
$ | (4,373 | ) | $ | 1,428 | $ | 2,384 | |||||
Other comprehensive income (loss): |
||||||||||||
Adjustment for net periodic pension cost, net of taxes |
76 | 3 | (388 | ) | ||||||||
Adjustment for mark- to-market value of swap, net of taxes |
(67 | ) | | | ||||||||
COMPREHENSIVE INCOME (LOSS) |
$ | (4,364 | ) | $ | 1,431 | $ | 1,996 | |||||
SUPPLEMENTAL INFORMATION |
||||||||||||
Net sales and other revenue related parties |
$ | 4,360 | $ | 37,209 | $ | 43,583 | ||||||
Purchases related parties |
$ | 12,068 | $ | 13,752 | $ | 13,728 |
See Notes to Consolidated Financial Statements.
F-4
PROFESSIONAL VETERINARY PRODUCTS, LTD.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY
Years Ended July 31, 2009, 2008 and 2007
(in thousands)
Accumulated | ||||||||||||||||||||||||
Common | Additional | Other | ||||||||||||||||||||||
Shares | Common | Paid-in | Comprehensive | Retained | ||||||||||||||||||||
Issued | Stock | Capital | Loss | Earnings | Total | |||||||||||||||||||
BALANCE AT AUGUST 1, 2006 |
2,042 | $ | 2 | $ | 6,039 | $ | 0 | $ | 14,123 | $ | 20,164 | |||||||||||||
Issuance of stock |
56 | | 168 | | | 168 | ||||||||||||||||||
Redemption of stock |
(30 | ) | | (90 | ) | | | (90 | ) | |||||||||||||||
Net change in accounts receivable, stock |
| | (5 | ) | | | (5 | ) | ||||||||||||||||
Adjustment to initially apply FASB
Statement No.
158 |
| | | (388 | ) | | (388 | ) | ||||||||||||||||
Net income |
| | | | 2,384 | 2,384 | ||||||||||||||||||
BALANCE AT JULY 31, 2007 |
2,068 | 2 | 6,112 | (388 | ) | 16,507 | 22,233 | |||||||||||||||||
Issuance of stock |
7 | | 21 | | | 21 | ||||||||||||||||||
Redemption of stock |
(38 | ) | | (114 | ) | | | (114 | ) | |||||||||||||||
Net change in accounts receivable, stock |
| | 25 | | | 25 | ||||||||||||||||||
Change in unrecognized pension cost |
| | | 3 | | 3 | ||||||||||||||||||
Net income |
| | | | 1,428 | 1,428 | ||||||||||||||||||
BALANCE AT JULY 31, 2008 |
2,037 | 2 | 6,044 | (385 | ) | 17,935 | 23,596 | |||||||||||||||||
Issuance of stock |
| | | | | | ||||||||||||||||||
Redemption of stock |
(89 | ) | | (265 | ) | | | (265 | ) | |||||||||||||||
Net change in accounts receivable, stock |
| | | | | | ||||||||||||||||||
Change in unrecognized pension cost |
| | | 76 | | 76 | ||||||||||||||||||
Change in mark-to-market interest rate swap |
| | | (67 | ) | (67 | ) | |||||||||||||||||
Net income (loss) |
| | | | (4,373 | ) | (4,373 | ) | ||||||||||||||||
BALANCE AT JULY 31, 2009 |
1,948 | 2 | 5,779 | (376 | ) | 13,562 | 18,967 | |||||||||||||||||
See Notes to Consolidated Financial Statements.
F-5
PROFESSIONAL VETERINARY PRODUCTS, LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended July 31, 2009, 2008 and 2007
(in thousands)
July 31, | July 31, | July 31, | ||||||||||
2009 | 2008 | 2007 | ||||||||||
OPERATING ACTIVITIES |
||||||||||||
Net income (loss) |
$ | (4,373 | ) | $ | 1,428 | $ | 2,384 | |||||
Items not requiring (providing) cash |
||||||||||||
Depreciation and amortization |
1,829 | 1,702 | 1,427 | |||||||||
(Gain) loss on sale of property |
51 | (1 | ) | 81 | ||||||||
Retirement benefits |
212 | 342 | 602 | |||||||||
Deferred income tax |
(548 | ) | (181 | ) | (573 | ) | ||||||
Allowance for doubtful accounts |
(196 | ) | (14 | ) | (55 | ) | ||||||
Allowance for obsolete inventory |
(55 | ) | 55 | 64 | ||||||||
Equity in income from affiliate |
| (53 | ) | (116 | ) | |||||||
Loss on the sale of unconsolidated affiliate |
| 571 | | |||||||||
Changes in: |
||||||||||||
Receivables |
4,066 | 200 | (7,053 | ) | ||||||||
Inventory |
(1,146 | ) | 7,122 | (7,387 | ) | |||||||
Other current assets |
(2,247 | ) | (716 | ) | 1,066 | |||||||
Other assets |
(6 | ) | (1 | ) | (37 | ) | ||||||
Accounts payable |
(3,651 | ) | (8,567 | ) | 3,310 | |||||||
Other current liabilities |
(437 | ) | (703 | ) | 1,537 | |||||||
Total adjustments |
(2128 | ) | (244 | ) | (7,134 | ) | ||||||
Net cash provided by (used in) operating activities |
(6,501 | ) | 1,184 | (4,750 | ) | |||||||
INVESTING ACTIVITIES |
||||||||||||
Purchase of property and equipment |
(505 | ) | (1,726 | ) | (1,550 | ) | ||||||
Proceeds from sale of assets |
110 | 1 | 2 | |||||||||
Proceeds from the sale of unconsolidated affiliate |
| 1,400 | | |||||||||
Purchase of investments |
| (9 | ) | (30 | ) | |||||||
Cash value of life insurance |
(475 | ) | (466 | ) | (418 | ) | ||||||
Sale of investments |
| 40 | | |||||||||
Net cash used in investing activities |
(870 | ) | (760 | ) | (1,996 | ) | ||||||
FINANCING ACTIVITIES |
||||||||||||
Net borrowings under line-of-credit agreement |
7,427 | 914 | 5,843 | |||||||||
Proceeds from long-term debt |
| | 4,666 | |||||||||
Payments of long-term debt and capital lease obligation |
(368 | ) | (396 | ) | (5,246 | ) | ||||||
Proceeds from issuance of common stock |
| 46 | 163 | |||||||||
Payments from redemption of common stock |
(265 | ) | (114 | ) | (90 | ) | ||||||
Net cash provided by financing activities |
6,794 | 450 | 5,336 | |||||||||
Increase (Decrease) in Cash |
(577 | ) | 874 | (1,410 | ) | |||||||
Cash at beginning of year |
1,985 | 1,111 | 2,521 | |||||||||
Cash at end of year |
$ | 1,408 | $ | 1,985 | $ | 1,111 | ||||||
Supplemental cash flows information: |
||||||||||||
Non-cash periodic pension cost, net of taxes |
$ | 76 | $ | | $ | | ||||||
Non-cash unrealized loss on interest rate swap, net of taxes |
$ | (67 | ) | $ | | $ | | |||||
Interest paid |
$ | 1,112 | $ | 1,451 | $ | 1,880 | ||||||
Income taxes paid (refunded) |
$ | (168 | ) | $ | 1,967 | $ | 935 | |||||
See Notes to Consolidated Financial Statements.
F-6
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Nature of Operations Professional Veterinary Products, Ltd. (the Company), a Nebraska
corporation, is a wholesale distributor of animal health related pharmaceuticals and other
veterinary related items. Founded in 1982 and headquartered in Omaha, Nebraska, the Company
provides products and other services primarily to its shareholders. Shareholders are limited to the
ownership of one share of stock and must be a licensed veterinarian or business entity comprised of
licensed veterinarians.
Principles of Consolidation The consolidated financial statements include the accounts of
the Company and its wholly owned subsidiaries Exact Logistics, LLC (Exact Logistics) and ProConn,
LLC (ProConn). All significant intercompany accounts and transactions have been eliminated in
consolidation. Investments in companies in which the Company exercises significant influence, but
not control, are accounted for using the equity method of accounting. Investments in companies in
which the Company has less than a 20% ownership interest, and does not exercise significant
influence, are accounted for at cost.
Use of Estimates The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual amounts could differ from those
estimates.
Revenue Recognition The Company derives its revenue primarily from the sale of products and
agency agreements. Revenues are recognized as product is received by the customer and related
services are performed in accordance with all applicable revenue recognition criteria. For these
transactions, the Company applies the provisions of SEC Staff Accounting Bulletin No. 104, Revenue
Recognition. Agency sales are transactions presented on a net basis. The Company recognizes
revenue when there is pervasive evidence of an arrangement, title and risk of loss have passed,
delivery has occurred or the contractual obligations are met, the sales price is fixed or
determinable and collection of the related receivable is reasonably assured.
Cash The Companys cash funds are located in financial institutions in the United States.
Effective October 3, 2008 the FDICs insurance limits increased to $250,000. The increase in
federally insured limits is currently set to expire December 31, 2013. Deposits in these bank
accounts may, at times, exceed the $250,000 federally insured limit. At July 31, 2009, the
Companys cash accounts exceeded federally insured limits by approximately $1.2 million.
Accounts Receivable Accounts receivable arise in the normal course of business and are
reduced by a valuation allowance that reflects managements best estimate of the amounts that will
not be collected. In addition to reviewing delinquent accounts receivable, management considers
many factors in estimating its general allowance, including historical data, experience, credit
worthiness and economic trends. From time to time, management may adjust its assumptions for
anticipated changes in any of those or other factors expected to affect collectability.
Accounts that are unpaid after the due date bear interest at 1% per month. Accounts past due
more than 120 days are considered delinquent. Interest continues to accrue on delinquent accounts
until the account is past due more than one year, at which time interest accrual ceases and does
not resume until the account is no longer classified as delinquent. Delinquent receivables are
written off based on individual credit evaluation and specific circumstances of the customer.
Inventory Inventories consist substantially of finished goods held for resale and are stated
at the lower of cost or market, not in excess of net realizable value. Cost is determined primarily
by the weighted average cost method. The reserve for inventory obsolescence was $127 and $182 for
2009 and 2008, respectively.
F-7
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued):
Property and Equipment Property and equipment are stated at cost. Depreciation has been
calculated using primarily the straight-line method over the estimated useful lives of the
respective classes of assets as follows:
Buildings
|
40 years | |
Furniture, fixtures and equipment
|
7 years | |
Computer equipment
|
5 years | |
Software
|
3-5 years |
Leasehold improvements are amortized over the shorter of the remaining term of the lease or
the useful life of the improvement utilizing the straight-line method. Major additions and
betterments that extend the useful lives of property and equipment are capitalized and depreciated
over their estimated useful lives. Expenditures for maintenance and repairs are charged to expense
as incurred.
Capitalized Leases Property under capital leases is amortized over the lives of the
respective leases. Amortization of capital leases is included in depreciation expense.
Other
Intangible Assets Other identifiable intangible assets consist of the Company trademark
and loan origination fees. Trademarks have an indefinite life and therefore are not amortized. The
original trademark subject to amortization was $5. Accumulated amortization was $1 for 2009 and
2008. Loan origination fees constitute the Companys identifiable intangible asset subject to
amortization. The original loan origination fee subject to amortization was $36. Accumulated
amortization was $10 and $6 for July 31, 2009 and 2008, respectively. Amortization of the loan
origination fees is computed on a straight-line basis over the term of the related note.
Amortization expense of $4, $4, and $8 for the years ended July 31, 2009, 2008, and 2007,
respectively, is included in interest expense on the Consolidated Statements of Income and
Comprehensive Income. The estimated aggregate amortization expense for the seven succeeding fiscal
years is $26.
F-8
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued):
Income Taxes Deferred tax assets and liabilities are recognized for the tax effects of
differences between the financial statement and tax bases of assets and liabilities. A valuation
allowance is established to reduce deferred tax assets if it is more likely than not that a
deferred tax asset will not be realized. The Company files consolidated income tax returns with
its subsidiaries.
Direct Shipping and Handling Costs Freight and other direct shipping costs are included in
Cost of sales on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).
Direct handling costs are reflected in Operating, general and administrative expenses. Such
costs represent direct compensation costs of employees who store, move and prepare products for
shipment to the Companys customers. Direct handling costs were $4,166, $4,519, and $4,681 for
2009, 2008, and 2007 respectively.
Subsequent Events Subsequent events have been evaluated through October 29, 2009 which is
the date the financial statements were issued.
Fair Value of Financial Instruments The carrying amounts reported on the balance sheets
approximate the fair value for cash, accounts receivable, short-term borrowings and all other
variable rate debt (including borrowings under credit agreements). The carrying amounts reported
for long-term debt approximate fair value because the interest approximates current market rates
for financial instruments with similar maturities and terms.
Major Customer, Major Suppliers and Credit Concentrations Other financial assets and
liabilities, which potentially subject the Company to concentrations of credit risk, are trade
accounts receivable and trade payables. Two vendors comprised 52.2% of all purchases for the year
ended July 31, 2009. Two vendors comprised 48.3% and 48.2% of all purchases for the years ended
July 31, 2008 and 2007, respectively.
Common Stock On May 26, 2006, the Companys Board of Directors adopted an amendment to the
Companys Bylaws. Prior to the amendment, Article II (Stock); Section 5 (Share Redemption) of the
Bylaws allowed each shareholder the right to have his, her or its share of common stock redeemed by
the Company for the price paid by the shareholder for such share. The amendment granted the Company
discretion to repurchase or not to repurchase shares of common stock at the time of the
shareholders request for redemption. The Company may, but no longer has any obligation to,
repurchase such shares. Based on this amendment, management concluded that the Company no longer is
required to classify its stock as redeemable and mandatorily redeemable.
F-9
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued):
Earnings (Loss) Per Share Earnings (Loss) per share have been computed based on the
weighted-average common shares outstanding during each year. There are no securities that are
convertible to common stock that would cause further dilution.
Taxes Collected from Customers and Remitted to Governmental Authorities Taxes collected from
customers and remitted to governmental authorities are presented in the accompanying consolidated
statements of income (loss) and comprehensive income (loss) on a net basis. The amount of taxes
presented on a net basis in the accompanying financial statements was $3.9 million and $3.2 million
for the years ended July 31, 2009 and 2008, respectively.
Recent Accounting Pronouncements The Company adopted FASB SFAS No. 157, Fair Value
Measurements, as of August 1, 2008. This statement defines fair value, establishes a framework for
measuring fair value in generally accepted accounting principles, and expands disclosures about
fair value measurements. This statement emphasizes that fair value is a market-based measurement,
not an entity specific measurement. Therefore, a fair value measurement should be determined based
on the assumptions that market participants would use in pricing the asset or liability. As a
basis for considering market participant assumptions in fair value measurements, this statement
establishes a fair value hierarchy that distinguishes between the market participant assumptions
developed based on market data obtained from sources independent of the reporting entity and the
reporting entitys own assumptions about market participant assumptions developed based on the best
information available in the circumstances. This statement was effective for financial statements
issued for fiscal years beginning after November 15, 2007. The adoption of this statement did not
have a material effect on the Companys financial position, cash flows or results of operations.
In March 2008, FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities an amendment of FASB Statement No. 133. This statement is intended to enhance the
current disclosure framework in SFAS No. 133. The statement requires that objectives for using
derivative instruments be disclosed in terms of underlying risk and accounting designation. This
disclosure better conveys the purpose of derivative use in terms of the risks that the entity is
intending to manage. This statement was effective for financial statements issued for fiscal years
and interim periods beginning after November 15, 2008. This statement does not require comparative
disclosures for earlier periods at initial adoption. The adoption of this statement as of February
1, 2009 did not have a material effect on the Companys financial position, cash flows or results
of operations.
In May 2009, FASB issued SFAS No. 165, Subsequent Events. This statement is intended to
establish general standards of accounting for and disclosure of events that occur after the balance
sheet date but before financial statements are issued or are available to be issued. This
statement should be applied to the accounting for and disclosure of subsequent events. This
statement does not apply to subsequent events or transactions that are within the scope of other
applicable generally accepted accounting principles (GAAP) that provide different guidance on the
accounting treatment for subsequent events or transactions. This statement applies to both interim
financial statements and annual financial statements. The adoption of this statement as of June
15, 2009 did not have a material effect on the Companys financial position, cash flows or results
of operations.
In June 2009, FASB issued SFAS No. 168, The FASB Accounting Standards Codification and the
Hierarchy of Generally Accepted Accounting Principles a replacement of FASB Statement No. 162.
This statement will become the source of authoritative U.S. generally accepted accounting
principles (GAAP) recognized by the FASB to be applied by nongovernmental entities. Rules and
interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal
securities laws are also sources of authoritative GAAP for SEC registrants. On the effective date
of this statement, the codification will supersede all then-existing non-SEC accounting and
reporting standards. The adoption of this statement as of September 15, 2009 is not expected to
have a material effect on the Companys financial position, cash flows or results of operations.
F-10
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued):
Reclassifications Certain prior year amounts have been reclassified to conform to the July
31, 2009 presentation. Such reclassifications had no impact on results of operations or
stockholders equity.
NOTE 2 REBATES:
At each fiscal year end, the Company nets rebates due to stockholders against accounts
receivable. Rebates are paid in the form of credits against future purchases, never in cash. The
Company offset accounts receivable as follows:
2009 | 2008 | |||||||
Accounts receivable, net of allowance |
$ | 25,225 | $ | 28,445 | ||||
Less rebates |
650 | | ||||||
Accounts receivable, net |
$ | 24,575 | $ | 28,445 | ||||
Net sales and other revenue reported on the Consolidated Statements of Income (Loss) and
Comprehensive Income (Loss) were reduced by rebates as follows:
2009 | 2008 | 2007 | ||||||||||
Gross sales and other revenues |
$ | 300,379 | $ | 339,838 | $ | 345,699 | ||||||
Less rebates |
650 | | 3,000 | |||||||||
Net sales and other revenue |
$ | 299,729 | $ | 339,838 | $ | 342,699 | ||||||
NOTE 3 PROPERTY AND EQUIPMENT:
Major classes of property and equipment consist of the following:
2009 | 2008 | |||||||
Land |
$ | 1,762 | $ | 1,762 | ||||
Buildings |
5,217 | 5,217 | ||||||
Leasehold improvements |
606 | 636 | ||||||
Equipment |
11,140 | 10,982 | ||||||
18,725 | 18,597 | |||||||
Less accumulated depreciation |
10,196 | 8,698 | ||||||
8,529 | 9,899 | |||||||
Construction in progress |
189 | 301 | ||||||
Net property, plant, and equipment |
$ | 8,718 | $ | 10,200 | ||||
NOTE 4 INVESTMENT IN UNCONSOLIDATED AFFILIATES:
The Company holds a 5% interest in Agri-Laboratories, Ltd., which is carried at cost.
The amounts presented on the balance sheet consisted of:
2009 | 2008 | |||||||
Investment in Agri-Laboratories, Ltd. (cost method) |
144 | 144 | ||||||
$ | 144 | $ | 144 | |||||
F-11
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 5 COMMON STOCK:
On May 26, 2006, the Companys Board of Directors adopted an amendment to the Companys
Bylaws. Prior to the amendment, Article II (Stock); Section 5 (Share Redemption) of the Bylaws
allowed each shareholder the right to have his, her or its share of common stock redeemed by the
Company for the price paid by the shareholder for such share. The amendment granted the Company
discretion to repurchase or not to repurchase shares of common stock at the time of the
shareholders request for redemption. The Company may, but no longer has any obligation to,
repurchase such shares.
NOTE 6 INCOME TAXES:
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and
various states jurisdictions. With a few exceptions, the Company is no longer subject to U.S.
federal, state and local U.S. income tax examination by tax authorities for years before 2006.
Significant components of income tax expense are as follows:
2009 | 2008 | 2007 | ||||||||||
Current |
||||||||||||
Federal |
$ | (2,268 | ) | $ | 850 | $ | 1,561 | |||||
State |
45 | 133 | 229 | |||||||||
(2,223 | ) | 983 | 1,790 | |||||||||
Deferred |
||||||||||||
Federal |
(157 | ) | (154 | ) | (268 | ) | ||||||
State |
(391 | ) | (27 | ) | (47 | ) | ||||||
(548 | ) | (181 | ) | (315 | ) | |||||||
Total |
$ | (2,771 | ) | $ | 802 | $ | 1,475 | |||||
A reconciliation of income tax expense computed using the U.S. federal statutory income tax
rate of 34% of income before income taxes to the actual provision for income taxes is as follows:
2009 | 2008 | 2007 | ||||||||||
Expected tax at U.S. statutory rate |
$ | (2,429 | ) | $ | 758 | $ | 1,340 | |||||
State taxes, net of federal effect |
(363 | ) | 65 | 96 | ||||||||
Other, net |
21 | (21 | ) | 39 | ||||||||
$ | (2,771 | ) | $ | 802 | $ | 1,475 | ||||||
F-12
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 6 INCOME TAXES (continued):
Deferred tax assets and liabilities reflect the future tax consequences of events that have
already been recognized in the consolidated financial statements or income tax returns. At July 31,
the deferred tax asset and liability consisted of the following:
2009 | 2008 | |||||||
Current deferred tax asset (liability): |
||||||||
Uniform capitalization |
$ | 330 | $ | 326 | ||||
Interest rate swap |
44 | | ||||||
Allowance for doubtful accounts |
122 | 200 | ||||||
Legal fees |
40 | | ||||||
Net operating loss carryforward |
365 | | ||||||
Inventory valuation |
51 | 73 | ||||||
$ | 952 | $ | 599 | |||||
Noncurrent deferred tax asset (liability): |
||||||||
Excess of tax over book depreciation |
$ | (833 | ) | $ | (994 | ) | ||
Amortization |
18 | 24 | ||||||
Deferred compensation |
1,221 | 1,187 | ||||||
Capital loss in SERVCO |
40 | 40 | ||||||
$ | 446 | $ | 257 | |||||
The
Company has unused operating loss carryforwards for state income tax
purposes specifically allowable to various states aggregating
approximately $5,300, which expire between 2014 and 2029.
NOTE 7 NOTE PAYABLE AND LONG-TERM DEBT:
At July 31, long-term debt is summarized as follows:
2009 | 2008 | |||||||
Note payable, maturing in 2016, secured by certain
assets, 7.35% interest |
3,770 | 4,138 | ||||||
3,770 | 4,138 | |||||||
Less current portion |
400 | 371 | ||||||
$ | 3,370 | $ | 3,767 | |||||
F-13
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 7 NOTE PAYABLE AND LONG-TERM DEBT (continued):
The aggregate schedule of maturities of long-term debt subsequent to July 31, 2009 are as
follows:
2010 |
$ | 400 | ||
2011 |
433 | |||
2012 |
465 | |||
2013 |
501 | |||
2014 |
539 | |||
Thereafter |
1,432 | |||
$ | 3,770 | |||
In November 2006, the Company and its subsidiaries executed a Loan Agreement and related loan
documents (collectively Loan Documents) with First National Bank of Omaha (FNB). See Note 10 for
additional details of this agreement. The FNB term note is amortized over a ten year period with a
final maturity date of December 2016. The interest rate is fixed at 7.35% and the terms include
monthly installments of $55 beginning January 2007. As of July 31, 2009, the Company had $3,770
outstanding on the term note.
In November 2006, the Company and its subsidiaries executed a revolving line of credit
agreement with FNB. See Note 10 for additional details of this agreement. The revolving line of
credit at FNB provides for borrowings up to $40,000 ($37,500 beginning August 21, 2009) and
is scheduled to expire in December 2009. The amount outstanding under this credit facility was
$20,287 and $12,860 at July 31, 2009 and 2008, respectively. Under the current credit agreement,
interest is payable at 1.25% or 1.50% over the London InterBank Offered Rate (LIBOR), depending on
the Companys cash flow leverage ratios.
These debt and credit agreements contain certain covenants related to financial ratios as well
as restricting the Company from paying dividends. At July 30, 2009, the Company received a waiver of
non-compliance of certain loan covenants.
NOTE 8 RELATED PARTY TRANSACTIONS:
In the normal course of business the Company sells to its affiliate, board of directors and
key employees under normal terms and conditions. Accounts receivable, related parties on the
balance sheet include amounts receivable on demand from the following as of July 31:
2009 | 2008 | |||||||
Board of Directors |
319 | 649 | ||||||
Officer and employees |
29 | 14 | ||||||
$ | 348 | $ | 663 | |||||
Net sales on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
include sales to related parties as follows:
2009 | 2008 | 2007 | ||||||||||
Affiliate (SERVCO) |
$ | | $ | 32,452 | $ | 39,062 | ||||||
Board of Directors |
4,284 | 4,676 | 4,457 | |||||||||
Officer and employees |
76 | 81 | 64 | |||||||||
$ | 4,360 | $ | 37,209 | $ | 43,583 | |||||||
F-14
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 8 RELATED PARTY TRANSACTIONS (continued):
Accounts payable, related parties on the balance sheet include amounts payable on demand as of
July 31 from the following:
2009 | 2008 | |||||||
Jelecos |
175 | 154 | ||||||
Agri-Laboratories |
670 | 584 | ||||||
$ | 845 | $ | 738 | |||||
Purchases from Agri-Laboratories were $9,412, $12,072 and $13,728 for 2009, 2008 and 2007,
respectively. Purchases from Jelecos were $1,936 and $1,680 for 2009 and 2008, respectively.
Purchases from Revenue Analytics were $720 for 2009.
NOTE 9 PROFIT-SHARING, 401(k) AND RETIREMENT PLAN:
The Company provides a non-contributory profit-sharing plan covering all full-time employees
who qualify as to age and length of service. It has been the Companys policy to make contributions
to the plan as provided annually by the Board of Directors. The total provision for the
contribution to the plan was $0, $107 and $349 for 2009, 2008 and 2007, respectively.
The Company also provides a contributory 401(k) retirement plan covering all full-time
employees who qualify as to age and length of service. It is the Companys policy to match a
maximum allowable 100% employee contribution with a 3% contribution. The total provision to the
plan was $295, $334 and $306 for 2009, 2008 and 2007, respectively.
On January 1, 2003, the Company adopted a Supplemental Executive Retirement Plan (SERP). The
SERP is a nonqualified defined benefit plan pursuant to which the Company will pay supplemental
pension benefits to certain key employees upon retirement based upon the employees years of
service and compensation. As of July 31, 2007, the Company adopted the provisions of SFAS No. 158,
Employers Accounting for Defined Benefit Pension and Other Postretirement Plans and in accordance
therewith reflected the underfunded status of the plan in its balance sheet at such date.
Prospectively, the Company adjusted the liability to reflect the current funded status of the plan.
Any gains or losses that arose during the period but are not recognized as components of net
periodic benefit cost was recognized as a component of other comprehensive income. The adoption of
SFAS No. 158 resulted in the recognition of $646 of unrecognized actuarial losses which arose
during the period ended July 31, 2007 and a corresponding increase in the defined benefit pension
plan liability at July 31, 2007. Such unrecognized losses, less deferred taxes of $258 were
debited to other comprehensive income. The adoption of SFAS No. 158 had no effect on the Companys
consolidated statement of income for the period ended July 31, 2007.
For the years ended July 31, 2009 and 2008, benefits accrued and expensed were $324 and $344,
respectively. The vested benefit obligation and accumulated benefit obligation were $2,836 and
$2,955, respectively, at July 31, 2009 and $2,474 and $2,729, respectively, at July 31, 2008. The
plan is an unfunded supplemental retirement plan and is not subject to the minimum funding
requirements of the Employee Retirement Income Security Act (ERISA). While the SERP is an unfunded
plan, the Company is informally funding the plan through life insurance contracts on the
participants. The life insurance contracts had cash surrender values of $2,709 and $2,238 at July
31, 2009 and 2008, respectively.
F-15
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 9 PROFIT-SHARING, 401(k) AND RETIREMENT PLAN (continued):
The following set forth the change in benefit obligations, change in plan assets, funded
status and amounts recognized in the balance sheet as of July 31 for the Companys SERP:
2009 | 2008 | |||||||
Change in Benefit Obligation: |
||||||||
Projected benefit obligation July 31 |
$ | 2,968 | $ | 2,628 | ||||
Service cost |
97 | 138 | ||||||
Interest cost |
186 | 164 | ||||||
Actuarial (gain)/loss |
(85 | ) | 38 | |||||
Benefits paid |
(112 | ) | | |||||
Plan Amendments |
| | ||||||
Projected benefit obligation July 31 |
$ | 3,054 | $ | 2,968 | ||||
Fair Value of Plan Assets July 31 |
$ | | $ | | ||||
Funded Status: |
||||||||
Funded status |
$ | (3,054 | ) | $ | (2,968 | ) | ||
Unrecognized actuarial loss |
| | ||||||
Unrecognized prior service cost |
| | ||||||
Net amount recognized as accrued retirement
benefits |
$ | (3,054 | ) | $ | (2,968 | ) | ||
Current liability |
$ | (243 | ) | $ | (115 | ) | ||
Noncurrent liability |
(2,811 | ) | (2,853 | ) | ||||
$ | (3,054 | ) | $ | (2,968 | ) | |||
As of July 31, 2009 and 2008, the following were recognized as components of other
comprehensive income not yet recognized as components of net periodic benefit costs:
July 31, 2009 | July 31, 2008 | |||||||
Unrecognized prior service cost |
$ | (240 | ) | $ | (275 | ) | ||
Unrecognized actuarial losses |
$ | (276 | ) | $ | (367 | ) | ||
Deferred taxes |
207 | 257 | ||||||
Recognized in other comprehensive income (loss), net of tax |
$ | (309 | ) | $ | (385 | ) | ||
The estimated net actuarial loss and prior service cost that will be amortized from
accumulated other comprehensive income into net periodic benefit cost over the next year is $35 and
$7, respectively.
F-16
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 9 PROFIT-SHARING AND 401(k) RETIREMENT PLAN (continued):
Net periodic benefit costs for the Companys SERP for the years ended July 31 included the
following components:
2009 | 2008 | 2007 | ||||||||||
Service cost |
$ | 97 | $ | 138 | $ | 144 | ||||||
Interest cost |
186 | 164 | 149 | |||||||||
Amortization of prior losses |
7 | 7 | 12 | |||||||||
Amortization of unrecognized prior service costs |
34 | 35 | 38 | |||||||||
Net periodic cost |
$ | 324 | $ | 344 | $ | 343 | ||||||
The weighted average discount rate and rate of increase in compensation levels used to compute
the actuarial present value of projected benefit obligations and net benefit cost were 5.50% and
6.25%, respectively, at July 31, 2009 and 6.25% and 4.00%,
respectively, at July 31, 2008 and 2007. The
measurement date of the SERP is equal to the Companys fiscal year end date of July 31.
The net benefit payments, which reflect expected future service, as appropriate, expected to
be paid in each of the next five fiscal years are $243, $243, $243, $243, and $243 for fiscal years
ending July 31, 2010, 2011, 2012, 2013, and 2014, respectively. The aggregate amount expected to
be paid for the five fiscal years thereafter is $1,212.
NOTE 10 COMMITMENTS AND CONTINGENT LIABILITIES:
Operating Leases The Company has operating leases covering certain property, equipment, and
computer hardware and software expiring at various dates through 2013.
F-17
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 10 COMMITMENTS AND CONTINGENT LIABILITIES (continued):
Future minimum lease payments under operating leases that have initial or remaining
non-cancelable lease terms in excess of one year at July 31, 2009 are as follows:
Operating | ||||
2010 |
$ | 1,047 | ||
2011 |
406 | |||
2012 |
251 | |||
2013 |
126 | |||
Thereafter |
51 | |||
Total minimum payments |
$ | 1,881 | ||
Lease expense was $1,095, $900 and $1,065 for the years ended July 31, 2009, 2008 and 2007,
respectively.
Stock Redemption The Bylaws grant the Company discretion to repurchase or not to repurchase
shares of common stock at the time of the shareholders request for redemption. The Company may,
but no longer has any obligation to, repurchase such shares. See Note 5 for additional information.
Other The Company is subject to claims and other actions arising in the ordinary course of
business. Some of these claims and actions have resulted in lawsuits where the Company is a
defendant. Management believes that the ultimate obligations, if any, which may result from
unfavorable outcomes of such lawsuits, will not have a material adverse effect on the financial
position, results of operations or cash flows of the Company and such obligations, if any, would be
adequately covered by insurance.
Agreements In November 2006, the Company and its subsidiaries executed a Loan Agreement and
related loan documents (collectively Loan Documents) with First National Bank of Omaha (FNB).
The obligations of the Company and its subsidiaries under the Loan Documents are joint and several.
Pursuant to the terms of the Loan Documents, FNB may loan to the Company and its subsidiaries up
to $44,700, which includes a $40,000 ($37,500 beginning August 21, 2009) revolving
loan facility and a $4,700 term loan facility.
The Term Note is amortized over a ten year period with a final maturity date of December 1,
2016. The interest rate is fixed at 7.35% per annum. Upon an event of default, the Term Note
shall bear interest at the LIBOR Rate as determined by FNB plus 7.50% per annum. This Term Note
may not be prepaid without obtaining the consent of FNB and payment of the prepayment fee as
calculated therein. Installments of principal and interest in the amount of $55 are due on the
first day of each month until and including November 1, 2016. On December 1, 2016, all unpaid
principal and interest thereon shall be due and payable. As of
July 31, 2009, the Company had $3,800 outstanding on the Term Note.
FNB shall provide advances to the Company from the Revolving Note in the maximum aggregate
amount of $40,000 ($37,500 beginning August 21, 2009), which advances will be used as
needed by the Company for working capital, through the termination date of December 1, 2009.
Interest shall be paid at a variable rate, reset monthly equal to the LIBOR as determined by FNB
plus (i) 1.25% per annum when the cash flow leverage ratio is less than or equal to 3.00 to 1.00 or
(ii) 1.50% per annum when the cash flow leverage ratio is more than 3.00 to 1.00.
The Loan Agreement imposes certain financial covenants, and the Company shall not, without the
consent of FNB, permit its minimum tangible net worth to be less than
$17,000 or its cash flow
leverage ratio to be equal to or greater than 3.50 to 1.00. The loans may be accelerated upon
default. Event of default provisions include, among other things, the Companys failure to (i) pay
amounts when due and to (ii) perform any material condition or comply with any material promise or
covenant of the Loan Documents. The Revolving Note and Term Note are secured by substantially all
of the assets of the Company and its subsidiaries, including the Companys headquarters in Omaha.
The Company is also restricted from paying dividends by these credit facilities.
On November 19, 2008, the Company and FNB amended the Loan Agreement to allow the Company to
enter into interest rate swap transactions from time-to-time. Pursuant to that amendment,
F-18
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 10 COMMITMENTS AND CONTINGENT LIABILITIES (continued):
interest shall be paid on the revolving note at a variable rate, reset monthly, equal to LIBOR Rate
as determined by Lender plus (i) 1.25% per annum when the cash flow leverage ratio is less than or
equal to 3.00 or 1.00 (ii) 1.50% per annum when the cash flow leverage ratio is more than 3.00 to
1.00. As a result of the interest rate swap, the Company is paying effective interest rate of 4.59%
for borrowings up to $10,000 for the period ending July 31, 2009. Upon the event of default,
the Revolving Note shall bear interest at the LIBOR as determined by FNB plus 7.50% per annum. As
of July 31, 2009, the variable interest rate at which the Revolving Note accrued interest was
1.81%, and the Company had approximately $20,300 outstanding thereunder.
On August 21, 2009, the Company entered into Amendment No. 3 to the Loan Agreement with FNB
dated November 14, 2006, as amended on September 17, 2007 and November 19, 2008. The Company has
requested that certain terms and conditions of the Loan Agreement be amended to decrease the
principal amount of the revolving credit facility provided by the
Loan Agreement from $40,000
to $37,500. Whereas, the Company has requested that FNB loan up to
$42,100 to the
Company via a $37,500 revolving credit facility and a $4,700 term loan facility, the
proceeds of this will be used to refinance existing indebtedness of the Company and to provide the
Company with working capital support. The Company shall pay FNB a
non-usage fee at the rate of .10% per annum of the unused portion of
the $37,500 revolving loan. The non-usage fee shall
be payable in arrears on each January 1, April 1, July 1, and October 1 and on the termination
date.
On January 3, 2007, the Company entered into Amendment No. 3 to lease agreement with Kinsley
Equities II Limited Partnership relating to its York, Pennsylvania property. The agreement
extended the lease term from July 31, 2007 to July 31, 2010. The minimum lease payments are $454
and $450, for the fiscal years ended July 31, 2009 and 2010, respectively.
On May 18, 2007, the Companys Audit Committee recommended and the Board of Directors approved
the dismissal of Quick & McFarlin upon its completion of the audit and the filing of the Form 10-K
for the fiscal year ended July 31, 2007 and the retention of BKD, LLP (BKD) as the Companys
independent accountant beginning with the fiscal year ended July 31, 2008. Quick & McFarlin
audited the Companys financial statements for each of the five fiscal years in the period ended
July 31, 2006.
On September 17, 2007, the Company entered into Amendment No. 1 to the Loan Agreement dated
November 14, 2006 with FNB. Hills Pet Nutrition Sales, Inc. (Hills) requested that the
limitation on purchase money security interest liens under the Loan Agreement be amended to grant
Hills a purchase money security interest in all products that the Company acquires from Hills
including but not limited to Hills Prescription Diet and Hills Science Diet, together with all
proceeds from the sale of such branded products.
On July 14, 2008, the Company entered into a Stock Purchase Agreement (Agreement) with
American Animal Hospital Association (AAHA) and AAHA Services Corporation (SERVCO) pursuant to
which the Company sold to AAHA all of its shares of common stock in SERVCO, which represented 20%
F-19
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 10 COMMITMENTS AND CONTINGENT LIABILITIES (continued):
of the
total issued and outstanding shares of SERVCO for an aggregate
purchase price of $1,400. Effective at closing, the Company was no longer entitled to elect a board member on
SERVCOs Board of Directors, and Dr. Lionel Reilly, then the Companys Chief Executive Officer and
President, resigned as a director of SERVCO. The Company also agreed to cooperative with AAHA and
SERVCO to transition the logistics support previously provided by the Company. Both AAHA and
SERVCO agreed not to attempt to retain or hire any employee of the Company for a one year period
commencing on July 14, 2008.
On December 27, 2006, the Company and Jelecos entered into a statement of work agreement for
consulting services. Jelecos provides the Company with strategic technology consulting services
including, but not limited to, project analysis, staffing analysis, product and process evaluation,
capacity analysis and overall infrastructure analysis as related to current and future business
objectives. The estimated monthly recurring fee is approximately $144.
On March 21, 2008, the Company and Revenue Analytics entered into a statement of work
agreement for consulting services through July 31, 2008. The Company partnered with Revenue
Analytics to develop targeted pricing strategies, processes and monitoring capabilities at the
customer segment level. The estimated monthly recurring fee was
approximately $110 for four
months. On May 27, 2009, the Company and Revenue Analytics entered into a third statement of work
agreement for consulting services through May 31, 2010. The fees paid through July 31, 2009 are
$720.
F-20
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 11 DERIVATIVE FINANCIAL INSTRUMENTS:
As a strategy to maintain acceptable levels of exposure to the risk of changes in future cash
flows due to interest rate fluctuations, the Company entered into an interest rate swap agreement
for a portion of its floating rate debt. Pursuant to the agreement, the Company receives interest
from the counterparty at LIBOR and pays interest to the counterparty at a fixed rate of 3.09% on
notional amounts of $10,000 at July 31, 2009. As a result of the interest rate swap, the Company
is paying an effective interest rate of 4.59% for borrowings up to $10,000 for the period ending
July 31, 2009. Under the agreement, the Company pays or receives the net interest monthly, with
the monthly settlements included in interest expense.
Management has designated the interest rate swap agreement as a cash flow hedging instrument.
For derivative instruments that are designated and qualify as a cash flow hedge, the effective
portion of the gain or loss on the derivative is reported as a component of other comprehensive
income. Gains and losses on the valuation of the derivative representing either hedge
ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in
current earnings.
The table below presents certain information regarding the Companys interest rate swap
agreement designated as a cash flow hedge. The Company did not have any derivative instruments at
July 31, 2009 that were not designated as hedging instruments under FAS 133.
July 31, | July 31, | |||||||
2009 | 2008 | |||||||
Fair value of interest rate swap agreement |
$ | (111 | ) | $ | | |||
Balance sheet location of fair value amount |
Current Liabilities | | ||||||
Loss recognized in other comprehensive
income (effective portion-net of tax) |
$ | (67 | ) | $ | | |||
Loss reclassified from accumulated other
comprehensive income into income
(effective portion) |
$ | (162 | ) | $ | | |||
Location of loss reclassified from
accumulated other comprehensive income
into income |
Interest Expense | | ||||||
Gain or loss recognized in income
(ineffective portion and amount excluded
from effectiveness testing) |
$ | | $ | | ||||
Location of gain (loss) recognized in
income (ineffective portion and amount
excluded from effectiveness testing) |
| |
NOTE 12 DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS:
Effective August 1, 2008, the Company adopted SFAS 157, Fair Value Measurements. SFAS 157
defines fair value, establishes a framework for measuring fair value and expands disclosures about
fair value measurements. SFAS 157 has been applied prospectively as of the beginning of the year.
F-21
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 12 DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS (continued):
SFAS 157 defines fair value as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date.
SFAS 157 also establishes a fair value hierarchy which requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value. The
standard describes three levels of inputs that may be used to measure fair value:
Level 1 | Quoted prices in active markets for identical assets or liabilities | ||
Level 2 | Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities | ||
Level 3 | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities |
Following is a description of the valuation methodologies used for instruments measured at
fair value on a recurring basis and recognized in the accompanying consolidated balance sheet, as
well as the general classification of such instruments pursuant to the valuation hierarchy.
Interest Rate Swap Agreement
The fair value is estimated by a third party using inputs that are observable or that can be
corroborated by observable market data and, therefore, are classified within Level 2 of the
valuation hierarchy.
The following table presents the fair value measurements of assets and liabilities recognized
in the accompanying consolidated balance sheet measured at fair value on a recurring basis and the
level within the SFAS 157 fair value hierarchy in which the fair value measurements fall at July
31, 2009:
Fair Value Measurements Using | ||||||||||||||||
Quoted Prices | ||||||||||||||||
in Active | Significant | |||||||||||||||
Markets for | Other | Significant | ||||||||||||||
Identical | Observable | Unobservable | ||||||||||||||
Assets | Inputs | Inputs | ||||||||||||||
Fair Value | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
Interest rate swap agreement |
$ | (111 | ) | $ | | $ | (111 | ) | $ | |
F-22
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 13 SIGNIFICANT ESTIMATES AND CONCENTRATIONS
Current Economic Conditions The current economic environment presents distributors with
unprecedented circumstances and challenges, which in some cases have resulted in large declines in
the fair value of investments and other assets, declines in the volume of business, constraints on
liquidity and difficulty obtaining financing. The financial statements have been prepared using
values and information currently available to the Company.
Current economic and financial market conditions could adversely affect the Companys results
of operations in future periods. The current instability in the financial markets may make it
difficult for certain of the Companys customers to obtain financing, which may significantly
impact the volume of future sales which could have an adverse impact on the Companys future
operating results.
In addition, given the volatility of current economic conditions, the values of assets and
liabilities recorded in the financial statements could change rapidly, resulting in material future
adjustments in investment values, allowances for accounts and notes receivable, net realizable
value of inventory, realization of deferred tax assets and valuation of intangibles that could
negatively impact the Companys ability to meet debt covenants or maintain sufficient liquidity.
F-23
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 14 SEGMENT INFORMATION:
The Company has three reportable segments: Wholesale Distribution, Logistics Services, and
Direct Customer Services. The Wholesale Distribution segment is a wholesaler of animal health
products. This segment distributes products primarily to licensed veterinarians or business
entities comprised of licensed veterinarians. The Logistics Services segment provides logistics and
distribution service operations for vendors of animal health products and business-to-business type
transactions. The Logistic Services segment distributes products primarily to other animal health
companies. The Direct Customer Services segment acts as a supplier of animal health products to the
producer or consumer. Animal health products are shipped to locations closer to the final
destination. The segments trucking operations transport the products directly to the producer or
consumer.
The accounting policies of the segments are the same as those described in the summary of
significant accounting policies as detailed in Note 1 to these consolidated financial statements.
The Company evaluates performance based on profit or loss from operations before income taxes. The
Companys reportable segments are strategic business units that serve different types of customers
in the animal health industry. The separate financial information of each segment is presented
consistent with the way results are regularly evaluated by the chief operating decision maker in
deciding how to allocate resources and in assessing performance.
Since the Companys reportable segments all provide essentially the same products and
services, the Company believes it would be impracticable to report the revenue from external
customers for each product and service or each group of similar products and services in accordance
with paragraph 37 of SFAS No. 131, Disclosures About Segments of an Enterprise and Related
Information.
F-24
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 14 SEGMENT INFORMATION (continued):
The following table summarizes the Companys operations by business segment:
Direct | ||||||||||||||||||||
Wholesale | Logistics | Customer | Consolidated | |||||||||||||||||
Distribution | Services | Services | Eliminations | Total | ||||||||||||||||
For the year ended
July 31, 2009 |
||||||||||||||||||||
Net sales and other revenue |
$ | 294,377 | $ | 284 | $ | 55,566 | $ | (50,498 | ) | $ | 299,729 | |||||||||
Cost of sales |
268,275 | 240 | 50,733 | (52,914 | ) | 266,334 | ||||||||||||||
Operating, general and
administrative expenses |
32,459 | | 7,345 | | 39,804 | |||||||||||||||
Operating income (loss) |
(6,358 | ) | 44 | (2,512 | ) | 2,417 | (6,409 | ) | ||||||||||||
Income before taxes |
$ | (7,143 | ) | $ | 44 | $ | (2,462 | ) | $ | 2,417 | $ | (7,144 | ) | |||||||
Business segment assets |
$ | 79,017 | $ | 395 | $ | 11,823 | $ | (11,502 | ) | $ | 79,733 | |||||||||
For the year ended
July 31, 2008 |
||||||||||||||||||||
Net sales and other revenue |
$ | 338,376 | $ | 1,452 | $ | 63,532 | $ | (63,522 | ) | $ | 339,838 | |||||||||
Cost of sales |
301,511 | 1,495 | 55,780 | (63,190 | ) | 295,596 | ||||||||||||||
Operating, general and
administrative expenses |
33,045 | | 7,389 | | 40,434 | |||||||||||||||
Operating income |
3,820 | (43 | ) | 363 | (332 | ) | 3,808 | |||||||||||||
Income before taxes |
$ | 2,230 | $ | (43 | ) | $ | 375 | $ | (332 | ) | $ | 2,230 | ||||||||
Business segment assets |
$ | 80,392 | $ | 351 | $ | 14,906 | $ | (14,455 | ) | $ | 81,194 | |||||||||
For the year ended
July 31, 2007 |
||||||||||||||||||||
Net sales and other revenue |
$ | 338,535 | $ | 306 | $ | 57,085 | $ | (53,227 | ) | $ | 342,699 | |||||||||
Cost of sales |
303,949 | 258 | 50,001 | (53,086 | ) | 301,122 | ||||||||||||||
Operating, general and
administrative expenses |
29,106 | | 6,971 | | 36,077 | |||||||||||||||
Operating income |
5,480 | 48 | 113 | (141 | ) | 5,500 | ||||||||||||||
Income before taxes |
$ | 3,860 | $ | 48 | $ | 92 | $ | (141 | ) | $ | 3,859 | |||||||||
Business segment assets |
$ | 87,297 | $ | 394 | $ | 13,075 | $ | (12,522 | ) | $ | 88,244 |
F-25
PROFESSIONAL VETERINARY PRODUCTS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended July 31, 2009, 2008 and 2007
(in thousands, except per share data)
NOTE 15 SELECTED QUARTERLY FINANCIAL DATA:
The following presents certain unaudited quarterly financial data and certain audited year-end
financial data. The unaudited data reflects all adjustments which are, in the opinion of
management, necessary to a fair statement of the results for the interim periods presented.
Quarters ended | Year ended | ||||||||||||||||||||||
October 31, | January 31, | April 30, | July 31, | July 31, | |||||||||||||||||||
2006 | 2007 | 2007 | 2007 | 2007 | |||||||||||||||||||
Revenues |
$ | 89,816 | $ | 87,478 | $ | 78,520 | $ | 86,885 | $ | 342,699 | |||||||||||||
Gross profit |
10,048 | 10,797 | 9,362 | 11,370 | 41,577 | ||||||||||||||||||
Operating income |
992 | 1,300 | 684 | 2,524 | 5,500 | ||||||||||||||||||
Net income |
419 | 468 | 85 | 1,412 | 2,384 | ||||||||||||||||||
Net income per
common share |
$ | 205.18 | $ | 229.79 | $ | 41.78 | $ | 689.59 | $ | 1,169.27 | |||||||||||||
Common shares
Outstanding |
2,043 | 2,036 | 2,030 | 2,048 | 2,039 |
Quarters ended | Year ended | |||||||||||||||||||
October 31, | January 31, | April 30, | July 31, | July 31, | ||||||||||||||||
2007 | 2008 | 2008 | 2008 | 2008 | ||||||||||||||||
Revenues |
$ | 89,601 | $ | 91,016 | $ | 82,683 | $ | 76,538 | $ | 339,838 | ||||||||||
Gross profit |
9,564 | 12,895 | 11,003 | 10,780 | 44,242 | |||||||||||||||
Operating income |
234 | 2,704 | 644 | 226 | 3,808 | |||||||||||||||
Net income (loss) |
(34 | ) | 1,511 | 248 | (297 | ) | 1,428 | |||||||||||||
Net income (loss) per
common share |
$ | (16.52 | ) | $ | 737.29 | $ | 121.87 | $ | (145.73 | ) | $ | 697.92 | ||||||||
Common shares
outstanding |
2,058 | 2,049 | 2,040 | 2,038 | 2,046 |
Quarters ended | Year ended | |||||||||||||||||||
October 31, | January 31, | April 30, | July 31, | July 31, | ||||||||||||||||
2008 | 2009 | 2009 | 2009 | 2009 | ||||||||||||||||
Revenues |
$ | 85,795 | $ | 64,727 | $ | 75,291 | $ | 73,916 | $ | 299,729 | ||||||||||
Gross profit |
8,187 | 9,937 | 7,915 | 7,356 | 33,395 | |||||||||||||||
Operating income (loss) |
(2,206 | ) | 12 | (1,747 | ) | (2,468 | ) | (6,409 | ) | |||||||||||
Net income (loss) |
(1,760 | ) | (33 | ) | (1,146 | ) | (1,434 | ) | (4,373 | ) | ||||||||||
Net income (loss) per
common share |
$ | (868.64 | ) | $ | (16.54 | ) | $ | (581.43 | ) | $ | (820.70 | ) | $ | (2,196.65 | ) | |||||
Common shares
outstanding |
2,026 | 1,995 | 1,971 | 1,952 | 1,948 |
F-26
(b) Exhibits
Regulation S-K | ||
Exhibit Number | Document | |
3.1
|
Second Amended and Restated Articles of Incorporation of Professional Veterinary Products (1) | |
3.2
|
Second Amended and Restated Bylaws of Professional Veterinary Products, Ltd. (2) | |
3.3
|
Amendment to Second Amended and Restated Bylaws of Professional Veterinary Products, Ltd. (3) | |
4.1
|
Certificate of Professional Veterinary Products, Ltd. (4) | |
4.2
|
Second Amended and Restated Articles of Incorporation of Professional Veterinary Products, Ltd. (1) | |
4.3
|
Second Amended and Restated Bylaws of Professional Veterinary Products, Ltd. (2) | |
4.4
|
Amendment to Second Amended and Restated Bylaws of Professional Veterinary Products, Ltd. (3) | |
10.1
|
Sales Agency Agreement between Professional Veterinary Products, Ltd. and Bayer Corporation (4)* | |
10.2
|
Sales Agent Agreement between Professional Veterinary Products, Ltd. and Merial LLC (4)* | |
10.3
|
Supply and Distribution Agreement between Professional Veterinary Products, Ltd. and Schering-Plough Animal Health Corporation (4)* | |
10.4
|
Distribution Agreement between Professional Veterinary Products, Ltd. and Fort Dodge Animal Health (4) | |
10.5
|
Purchase and Sale Agreement between Professional Veterinary Products, Ltd., AAHA Services Corporation and American Animal Hospital Association (5) | |
10.6
|
Lease of building located in York, Pennsylvania between Professional Veterinary Products, Ltd. and Kinsley Equities II Limited Partnership (6) | |
10.7
|
Supplemental Executive Retirement Plan (7) | |
10.8
|
Lease dated October 1, 2005 among Professional Veterinary Products, Ltd. and Steve Lewis and Mike Mimms (8) | |
10.9
|
Lease Agreement dated November 8, 2005 between Professional Veterinary Products, Ltd. and Independent Veterinary Group, LLC (8) | |
10.10
|
Supplemental Executive Retirement Plan (effective January 1, 2006) (9) | |
10.11
|
Commercial Lease Extension and Addendum between Professional Veterinary Products, Ltd, and The Independent Veterinary Group LLC and ACH BRO LLC (10) | |
10.12
|
Separation Agreement with Cheryl Miller (11) | |
10.13
|
Loan Agreement with First National Bank of Omaha dated November 14, 2006 (12) | |
10.14
|
Revolving Note dated November 14, 2006, to First National Bank of Omaha (12) | |
10.15
|
Term Note dated November 14, 2006, to First National Bank of Omaha (12) | |
10.16
|
Form of Security Agreement dated November 14, 2006, with First National Bank of Omaha (12) | |
10.17
|
Deed of Trust, Security Agreement, Assignment of Leases and Rents and Fixture Filing dated November 14, 2006, in favor of First National Bank of Omaha (12) | |
10.18
|
Assignment of Rents and Leases dated November 14, 2006, in favor of First National Bank of Omaha (12) | |
10.19
|
Amendment No. 1 to Lease Agreement between Professional Veterinary Products, Ltd. and Kinsley Equities II Limited Partnership (13) | |
10.20
|
Amendment No. 2 to Lease Agreement between Professional Veterinary Products, Ltd. and Kinsley Equities II Limited Partnership (13) | |
10.21
|
Amendment No. 3 to Lease Agreement between Professional Veterinary Products, Ltd. and Kinsley Equities II Limited Partnership (13) | |
10.22
|
Amendment No. 1 dated September 17, 2007 to the Loan Agreement with First National Bank of Omaha dated November 14, 2006 (14) | |
10.23
|
Stock Purchase Agreement among the Company, American Animal Hospital Association, and AAHA Services Corporation dated July 14, 2008 (15) | |
10.24
|
Amendment No. 2 dated November 19, 2008 to the Loan Agreement by and among Professional Veterinary Products, Ltd., its subsidiaries and First National Bank of Omaha (16) | |
10.25
|
2009 Livestock Products Distribution Agreement effective January 1, 2009 by and between Professional Veterinary Products, Ltd. and Pfizer Inc. (17)* | |
10.26
|
Amended and Restated Supplemental Executive Retirement Plan effective January 1, 2009 (17) |
II-1
Regulation S-K | ||
Exhibit Number | Document | |
10.27
|
Consulting Agreement dated January 30, 2009 between Professional Veterinary Products, Ltd. and Reico, Inc. (17) | |
10.28
|
Employment Agreement effective February 1, 2009, between Professional Veterinary Products, Ltd. And Stephen J. Price (18) | |
10.29
|
Severance Agreement dated April 1, 2009 between Professional Veterinary Products, Ltd. and Neal Soderquist (18) | |
11
|
Statement re Computation of Per Share Earnings (#) | |
12
|
Computation of Ratio of Earnings to Fixed Charges (#) | |
21
|
List of Subsidiaries (19) | |
31.1(A)
|
Certification pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by the Companys CEO (#) | |
31.1(B)
|
Certification pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by the Companys CFO (#) | |
32
|
Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by the Companys CEO and CFO (#) |
The following footnotes indicate a document previously filed as an exhibit to and incorporated by reference from the following:
(1) | Form 10-Q Quarterly Report for the period ended January 31, 2005 filed March 17, 2005. | |
(2) | Form 8-K Current Report dated March 7, 2005 and filed March 11, 2005. | |
(3) | Form 8-K Current Report dated May 26, 2006 and filed June 2, 2006. | |
(4) | Form S-1 Registration Statement No. 333-86629 filed on September 7, 1999. | |
(5) | Post-Effective Amendment No. 1 to the Form S-1 Registration Statement No. 333-86629 filed on November 3, 2000. | |
(6) | Form 10-K for the fiscal year ended July 31, 2002 filed on October 29, 2002. | |
(7) | Post-Effective Amendment No. 1 to the Form S-1 Registration Statement No. 333-72962 filed on August 29, 2003. | |
(8) | Post-Effective Amendment No. 2 to the Form S-1 Registration Statement No. 333-120426 filed on December 13, 2005. | |
(9) | Form 8-K Current Report dated October 19, 2006 and filed October 25, 2006. | |
(10) | Form 8-K Current Report dated August 2, 2006 and filed October 25, 2006. | |
(11) | Form S-1 Registration Statement filed on November 28, 2006. | |
(12) | Form 8-K Current Report dated November 14, 2006 and filed November 20, 2006. | |
(13) | Form 8-K Current Report dated January 3, 2007 and filed January 9, 2007. | |
(14) | Form 8-K Current Report dated September 17, 2007 and filed September 21, 2007. | |
(15) | Form 8-K Current Report dated July 14, 2008 and filed July 18, 2008. | |
(16) | Form 8-K Current Report dated November 19, 2008 and filed November 25, 2008. | |
(17) | Form 10-Q Quarterly Report for the period ended January 31, 2009 filed March 16, 2009 | |
(18) | Form 10-Q Quarterly Report for the period ended April 30, 2009 filed June 12, 2009 | |
(19) | Form S-1 Registration Statement No. 333-72962 filed on November 8, 2001. |
The following footnotes are references to the following:
(#) | Filed herewith. | |
(*) | Portions of these exhibits have been redacted pursuant to a request for confidential treatment which was granted by the Securities and Exchange Commission. |
II-2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: October 29, 2009
PROFESSIONAL VETERINARY PRODUCTS, LTD. | ||||||
By: | /s/ Stephen J. Price
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been
signed by the following persons on behalf of the Registrant and in the capacities and on the dates
indicated.
Signature | Capacity | Date | ||
/s/ Stephen J. Price
|
CEO (principal executive officer) |
October 29, 2009 | ||
/s/ Tara Chicatelli
|
Chief Financial Officer (principal financial officer) |
October 29, 2009 | ||
/s/ Rhonda Lee Pierce
|
Director | October 28, 2009 | ||
/s/ Donald R. Fogle
|
Director | October 26, 2009 | ||
/s/ James Alan Hoffmann
|
Director | October 27, 2009 | ||
/s/ Eileen Sam Holly Morris
|
Director | October 27, 2009 | ||
/s/ Scott A. Shuey
|
Director | October 26, 2009 | ||
/s/ Charles W. Luke
|
Director | October 26, 2009 | ||
/s/ Thomas E. Wakefield
|
Director | October 24, 2009 | ||
/s/ Vicky Wilkey
|
Director | October 29, 2009 | ||
/s/ Donald Janezic, Jr.
|
Director | October 27, 2009 |
II-3